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ABSTRACT

Investigation and engineering of polyketide biosynthetic pathways

by

Lei Sun, Doctor of Philosophy
Utah State University, 2017

Major Professor: Jixun Zhan
Department: Biological Engineering

Polyketides are a large family of natural products widely found in bacteria, fungi and plants,
which include many clinically important drugs such as tetracycline, chromomycin, spirolaxine,
endocrocin and emodin. They are synthesized from acyl- or malonyl-CoA precursors by polyketide
synthases (PKSs). Three types of PKSs are known to date. Type I PKSs are multifunctional
enzymes that are organized into modules, each of which harbors a set of distinct, non-iteratively
acting domains responsible for the catalysis of one cycle of polyketide chain elongation. Type II
PKSs are multienzyme complexes that carry a single set of iteratively acting enzymes. Type III
PKSs, also known as chalcone synthase-like PKSs, are homodimeric enzymes that essentially are
iteratively acting condensing enzymes.

In the first part of my dissertation research, I identified a type I nonreducing PKS (NR-PKS)
EmoA and a discrete thioesterase EmoB from the fungus Shiraia sp. strain Slf14 which produces
endocrocin and emodin, and heterologously expressed these enzymes in the industrial strains
Saachromyces cerevisiae and Pichia pastoris. In order to improve the production of target

iv

compounds endocrocin and emodin, we co-expressed a more efficient thioesterase ACTE1 with
EmoA and introduced an engineered acetyl-CoA carboxylase ACC1 into the biosynthetic pathway,
which provides more malonyl-CoA for polyketide biosynthesis. A decarboxylase TpcK was also
introduced to further increase the production of emodin. The second part was to characterize a
silent type II PKS gene cluster involved in the biosynthetic pathway of chromomycins in
Streptomyces reseiscleroticus and optimize the production of chromomycins by engineering two
regulatory genes to construct an efficient producing strain. The third part of this research was to
identify a type III PKS involved in the biosynthesis of spirolaxine (anti-Helicobacter pylori) in a
fungal strain Sporotrichum laxum. Heterologous expression of this PKS gene in Escherichia coli
produced alkylresorcinols which serve as the backbone to synthesize spirolaxine. In the fourth part
of my research, we manipulated the fermentation broth of E. coli harboring a type III PKS StTS
by supplying different nutrients including glucose and sodium pyruvate at different concentrations,
from which six novel flaviolin derivatives were produced. It provides a new approach to
biosynthesizing new molecules in the widely used heterologous host E. coli.
One goal of my dissertation research was to investigate and engineer the biosynthetic pathway
of pharmaceutically valuable compounds, such as chromomycin, spirolaxine and emodin, so that
we can produce the target compounds more efficiently for potential applications in industry. The
other goal was to utilize E. coli as a platform for heterologous expression of PKSs and engineering
of particular biosynthetic pathways to generate chemical diversity in natural products, such as
novel flaviolin derivatives and alkylresorcinols.

(189 pages)
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PUBLIC ABSTRACT

Investigation and engineering of polyketide biosynthetic pathways
Lei Sun
This research is focused on investigation and engineering of natural product biosynthetic
pathways for efficient production of pharmaceutically important molecules or generation of new
bioactive molecules for drug development.
Natural products are an important source of therapeutics, such as chromomycin (anti-cancer),
emodin (anti-inflammatory and anti-tumor) and sprolaxine (anti-Helicobacter pylori). Metabolic
engineering of natural product biosynthetic pathways shows its promise for creating and producing
valuable compounds with chemical diversity for drug discovery. One goal of this research is to
create highly efficient strains to biosynthesize valuable natural products. The engineered
Streptomyces roseiscleroticus strain constructed in this work showed higher titers of
chromomycins than previously reported, which was achieved by characterizing and engineering
the chromomycin biosynthetic gene cluster. I activated the polyketide biosynthetic pathway by
engineering two regulatory genes, and optimized the culture conditions to increase the titer of
chromomycins. The production of emodin nowadays mostly relies on conventional plant
cultivation and organic solvent extraction, which is time-consuming and cost-ineffective. This
work built a biosynthetic platform using industrial strains Saccharomyces cerevisiae and Pichia
pastoris with eight genes from fungi and yeast, which affords a more efficient biosynthetic process
of emodin.

On the other hand, we used Escherichia coli as a platform for heterologous expression of PKSs
and engineering of particular biosynthetic pathways to generate chemical diversity in natural
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products. The type III polyketide synthase (PKS) involved in the biosynthesis of spirolaxine was
identified in this research, which is important for complete elucidation of the biosynthetic pathway
of this anti-Helicobacter pylori natural product. Heterologous expression of this PKS in E. coli
generated five new pharmaceutically valuable alkylresorcinols. Addition of glucose or pyruvate
into the fermentation broths of E. coli expressing another type III PKS StTS resulted in a
significant change in the product profiles. Five new products are produced and structurally
characterized. Therefore, this work provides a new approach to generating new bioactive
molecules in E. coli, the most widely used heterologous expression host.

vii

DEDICATION
I dedicate this doctoral dissertation to my parents, Yulong Sun and Yifeng Tang, for nursing
me with affections and love and their dedicated partnership for success in my life.

To my wonderful wife, Jing Gao, and beloved daughter, Olivia Sun, for encouragement and
support along the way.

Lei Sun

viii

ACKNOWLEDGMENTS

I would like to express my gratitude to the American Heart Association grant
(16GRNT26430067) and the National Institutes of Health grants (AI065357 RM DP 008 and
AI089347) for supporting my research.

My deepest gratitude goes first and foremost to my major professor, Dr. Jixun Zhan, for his
outstanding guidance, generous support and constant encouragement. He leads me an access to the
academic world, and his mentoring is invaluable in the development of my future career. Without
his consistent and illuminating instructions, it would have been impossible for me to get so much
work done in four and half years and finish this dissertation. I would also like to thank my
committee members, Dr. David W. Britt, Dr. Jon Takemoto, Dr. Dong Chen and Dr. Elizabeth
Vargis for their suggestions and help, which helped me to grow professionally. I am also deeply
indebted to all my friends and colleagues, in the Metabolic Engineering Laboratory, for the
inspiring moments we shared and positive scientific atmosphere we created. Last but not least, I
would like to extend my thanks to all the staff in the Department of Biological Engineering,
especially Anne Martin, Kami McNeil, Levi Sanchez and Jed Moss for their help.

To all, thank you for being part of these past years and for those to come.

Lei Sun

ix

CONTENTS
ABSTRACT ................................................................................................................................... iii
PUBLIC ABSTRACT .....................................................................................................................v
DEDICATION .............................................................................................................................. vii
ACKNOWLEDGMENTS ........................................................................................................... viii
CONTENTS ................................................................................................................................... ix
LIST OF TABLES .........................................................................................................................xv
LIST OF FIGURES ..................................................................................................................... xvi
ABBREVIATIONS ................................................................................................................... xviii
CHAPTER I INTRODUCTION ......................................................................................................1
1.1 Background ............................................................................................................................1
1.2 Objectives ...............................................................................................................................7
1.3 A guide to the dissertation ......................................................................................................8
1.4 References ..............................................................................................................................9
CHAPTER II ENGINEERED PRODUCTION OF ENDOCROCIN AND EMODIN IN
YEAST ..........................................................................................................................................15
ABSTRACT ...............................................................................................................................15
2.1 Introduction ..........................................................................................................................16
2.2 Materials and Methods .........................................................................................................19
2.2.1 General method .............................................................................................................19
2.2.2 Strains and materials......................................................................................................20
2.2.3 Extraction and analysis of genomic DNA .....................................................................20

x

2.2.4 Amplification of intron-free genes and construction of heterologous expression
plasmids ..................................................................................................................................21
2.2.5 Transformation and fermentation of P. pastoris GS115 ...............................................25
2.2.6 Transformation and fermentation of S. cerevisiae BJ5464-NpgA ................................26
2.2.7 Polyketide biosynthesis .................................................................................................27
2.2.8 Purification and structural characterization of compounds 1, 2, 7 and 8 ......................28
2.3 Results ..................................................................................................................................29
2.3.1 Discovery and analysis of three putative iterative type I polyketide synthases ............29
2.3.2 Characterization of the products synthesized by NR-PKSs in S. cerevisiae .................31
2.3.3 Optimization of the polyketide production in S. cerevisiae ..........................................35
2.3.4 Production of emodin in P. pastoris GS115 ..................................................................41
2.3.5 The biosynthetic pathway of emodin and endocrocin ...................................................43
2.4 Conclusion ............................................................................................................................44
2.5 Acknowledgments ................................................................................................................45
2.6 References ............................................................................................................................45
CHAPTER III MANIPULATION OF TWO REGULATORY GENES FOR EFFICIENT
PRODUCTION OF CHROMOMYCINS IN STREPTOMYCES RESEISCLEROTICUS.............51
ABSTRACT ...............................................................................................................................51
3.1 Introduction ..........................................................................................................................52
3.2 Materials and Methods .........................................................................................................53
3.2.1 General method .............................................................................................................53
3.2.2 Microorganisms, culture conditions, and plasmids .......................................................54
3.2.3 DNA manipulation and sequence analysis ....................................................................55

xi

3.2.4 Heterologous expression of minimal PKS in S. lividans K4-114 .................................55
3.2.5 Overexpression of SARP in S. roseiscleroticus ............................................................56
3.2.6 Gene disruption of PadR in S. roseiscleroticus .............................................................57
3.2.7 Detection and purification of chromomycins A3 (3), A2 (4) and SEK15b (12) ...........58
3.2.8 Fermentation and products analysis ..............................................................................59
3.3 Results ..................................................................................................................................59
3.3.1 Analysis of the chromomycins biosynthesis gene cluster .............................................59
3.3.2 Heterologous expression of type II minimal PKSs in S. lividans K4-114 ....................63
3.3.3 Disruption of srcmRII in S. roseiscleroticus and products characterization .................65
3.3.4 Overexpression of SrcmRI in S. roseiscleroticus ..........................................................66
3.3.5 Optimization of the production of chromomycins A2 (4) and A3 (3) in engineered
S. roseiscleroticus ...................................................................................................................67
3.4 Conclusion ............................................................................................................................69
3.5 Acknowledgments ................................................................................................................70
3.6 References ............................................................................................................................70
CHAPTER IV IDENTIFICATION OF A TYPE III POLYKETIDE SYNTHASE INVOLVED
IN THE BIOSYNTHESIS OF SPIROLAXINE ............................................................................74
ABSTRACT ...............................................................................................................................74
4.1 Introduction ..........................................................................................................................75
4.2 Materials and Methods .........................................................................................................77
4.2.1 General method .............................................................................................................77
4.2.2 Strains and materials......................................................................................................78
4.2.3 Extraction and sequencing of genomic DNA ................................................................78

xii

4.2.4 Knockout of Sl-pks2 and Sl-pks1 from S. laxum ...........................................................78
4.2.5 Amplification of intron-free Sl-pks2 from the cDNA of S. laxum and construction of
pET28a-Sl-pks2 ......................................................................................................................81
4.2.6 In vivo polyketide biosynthesis .....................................................................................82
4.2.7 Purification and structural characterization of alkylresorcinols 16-20 ..........................82
4.2.8 Production and purification of His6-tagged Sl-PKS2 ....................................................85
4.2.9 PKS assay ......................................................................................................................85
4.3 Results ..................................................................................................................................86
4.3.1 Discovery and analysis of two putative type III PKS genes from S. laxum ..................86
4.3.2 Knockout of Sl-pks1 and Sl-pks2 from S. laxum ...........................................................87
4.3.3 Characterization of the products synthesized by Sl-PKS2 in E. coli ............................90
4.3.4 Functional characterization of Sl-PKS2 through in vitro reactions ...............................93
4.3.5 Proposed biosynthetic pathway of spirolaxine ..............................................................94
4.4 Conclusion ............................................................................................................................96
4.5 Acknowledgments ................................................................................................................96
4.6 References ...........................................................................................................................97
CHAPTER V EFFECTS OF EXOGENOUS NUTRIENTS ON POLYKETIDE
BIOSYNTHESIS IN ESCHERICHIA COLI ...............................................................................101
ABSTRACT .............................................................................................................................101
5.1 Introduction ........................................................................................................................102
5.2 Materials and Methods .......................................................................................................104
5.2.1 General method ...........................................................................................................104
5.2.2 Fermentation and product analysis ..............................................................................104

xiii

5.2.3 Time-course analysis of the production of 31-36 in E. coli BL21(DE3)/pET28a-stts
..............................................................................................................................................105
5.2.4 Purification and structural characterization of 31-36 ..................................................105
5.2.5 Bioconversion of flaviolin by E. coli BL21(DE3)/pET28a in the presence of glucose
or pyruvate ............................................................................................................................107
5.3 Results ................................................................................................................................108
5.3.1 Product analysis of the fermentation broths of E. coli BL21(DE3)/pET28a-stts
supplemented with different nutrients ..................................................................................108
5.3.2 Time course analysis of the production of 31-36 in E. coli BL21(DE3)/pET28a-stts
..............................................................................................................................................110
5.3.3 Purification and structural characterization of six flaviolin derivatives ......................112
5.3.4 Bioconversion of flaviolin by E. coli BL21(DE3)/pET28a .........................................117
5.3.5 Engineered biosynthetic pathway of flaviolin derivatives ..........................................118
5.4 Conclusion ..........................................................................................................................120
5.5 Acknowledgments ..............................................................................................................120
5.6 References ..........................................................................................................................121
CHAPTER VI SUMMARY AND ENGINEERING VALUE ....................................................125
6.1 Summary and future plan ...................................................................................................125
6.2 Engineering value ...............................................................................................................126
6.2.1 Engineered production of endocrocin and emodin in S. cerevisiae ...........................126
6.2.2 Engineered production of chromomycin A2 and A3 in S. roseiscleroticus ................127
6.2.3 Engineered production of alkylresorcinols and flaviolin derivatives in E. coli ..........128
6.3 References ..........................................................................................................................128

xiv

APPENDICES ............................................................................................................................130
APPENDIX A ..............................................................................................................................131
PERMISSION LETTERS ............................................................................................................131
APPENDIX B ..............................................................................................................................155
APPENDIX C ..............................................................................................................................156
APPENDIX D ..............................................................................................................................159
APPENDIX E ..............................................................................................................................162
APPENDIX F...............................................................................................................................164
CURRICULUM VITAE ..............................................................................................................165

xv

LIST OF TABLES

Tables

Pages

1. List of primers used in Chapter II ............................................................................................23
2. List of strains and plasmids used in Chapter II ........................................................................25
3.

1H-NMR

4.

13C-NMR

(500 MHz) data for 1, 2, 7 and 8 (DMSO-d6) ..........................................................35
(125 MHz) data for 1, 2, 7 and 8 (DMSO-d6, δ in ppm, J in Hz) ...........................35

5. List of strains and plasmids used in Chapter III ......................................................................55
6. List of primers used in Chapter III ...........................................................................................56
7. Putative functions of the genes of the chromomycin biosynthetic gene cluster ......................61
8.

1

H-NMR (300 MHz) and 13C-NMR (75 MHz) data for SEK15b (12) (DMSO-d6, δ in ppm,

J in Hz).....................................................................................................................................65
9. List of primers used in Chapter IV ..........................................................................................79
10. List of plasmids constructed in Chapter IV .............................................................................80
11. 13C-NMR (75 MHz) data for 32-36 (DMSO-d6)......................................................................... 116
12. 1H-NMR (300 MHz) data for 32-36 (DMSO-d6, δ in ppm, J in Hz) .....................................116

xvi

LIST OF FIGURES

Figures

Pages

1.

Structures of endocrocin (1) and emodin (2) ............................................................................3

2.

Structures of chromomycins A3 (3) and A2 (4) .......................................................................5

3.

Structure of spirolaxine (5) .......................................................................................................6

4.

Structure of flaviolin (6) ...........................................................................................................7

5.

Amino acid sequence alignment of CTB3 and HYP3 ............................................................19

6.

Different type I NR-PKSs and sequence alignment of related TEs ........................................31

7.

Analysis and structures of the products of S. cerevisiae BJ5464-NpgA harboring different
plasmids ..................................................................................................................................34

8.

The production of 1, 2 and 7 in the yeast ................................................................................37

9.

The effect of site-directed mutagenesis of ACC1 on the production of 1, 2 and 7 in the
yeast ........................................................................................................................................39

10. Improved production of 2 by engineering TpcK or HYP3 into the biosynthetic pathway .....41
11. HPLC analysis (420 nm) of the products of P. pastoris GS115-npgA-tpcK-emoA-acte1 (ii),
P. pastoris GS115 as control (i) ..............................................................................................42
12. Proposed biosynthetic pathway of 8 (A) as well as 1, 2 and 7 (B) .........................................44
13. Genetic organization of the srcm gene cluster ........................................................................60
14. Proposed biosynthetic pathway of chromomycins A2 and A3 ...............................................63
15. Heterologous expression of SrcmKPS in S. lividans K4-114 .................................................64
16. Activation of the silent srcm biosynthetic pathway by disrupting srcmRII in
S. roseiscleroticus ...................................................................................................................66

xvii

17. Activation of the silent srcm biosynthetic pathway by srcmRI overexpression in
S. roseiscleroticus ...................................................................................................................67
18. Production of 3 and 4 by the engineered S. roseiscleroticus strains .......................................69
19. Structures of spirolaxine and analogs .....................................................................................75
20. Amino acid sequence alignment of Sl-PKS1, Sl-PKS2, N. crassa ORAS and A. oryzae
CsyA ......................................................................................................................................87
21. Gene disruption of Sl-pks1 and Sl-pks2 ..................................................................................89
22. Expression of intron-free Sl-pks2 in E. coli BL21-CodonPlus (DE3)-RIL and analysis of
the in vivo polyketide products ...............................................................................................92
23. Purification of Sl-PKS2 from E. coli BL21-CodonPlus (DE3)-RIL and in vitro reactions ...94
24. Proposed biosynthetic pathway for spirolaxine (5) ................................................................96
25. Structures of flaviolin and biosynthesized derivatives (31-36) ............................................109
26. HPLC analysis (420 nm) of the effects of exogenous glucose (A) and pyruvate (B) on
polyketide biosynthesis in E. coli BL21(DE3) .....................................................................110
27. Time-course analysis of the product formation in E. coli BL21(DE3)/pET28a-stts in the
presence of 10 mg mL-1 glucose or sodium pyruvate ...........................................................111
28. Selected 1H-1H COSY and HMBC correlations for 32-36 ...................................................115
29. HPLC analysis (420 nm) of the bioconversion of flaviolin by IPTG-induced fermentation
broths of E. coli BL21(DE3)/pET28a ...................................................................................117
30. Proposed biosynthetic pathways of 31-36 in E. coli .............................................................120

xviii

ABBREVIATIONS
6-MSA

6-methylsalicylic acid synthase

11β-HSD1

11β-hydroxysteroid dehydrogenase type 1

ACAS

atrochrysone carboxylic acid synthase

ACC

acetyl-CoA carboxylase

ACP

acyl carrier protein

ACTE

atrochrysone carboxyl ACP thioesterase

ARO

aromatase

AS

acetosyringone

AT

acyltransferase

ATCC

American Type Culture Collection

BDL

benzenediol lactone

BLAST

Basic Local Alignment Search Tool

CLC

Claisen cyclase

CLF

chain length factor

CoA

coenzyme A

CYC

cyclase

DML

dihydromonacolin L

DTT

dithiothreitol

EDTA

ethylenediaminetetraacetic acid

ER

enoyl reductase

ESI-MS

electrospray ionization mass spectrometry

FDA

Food and Drug Administration

g

gram

xix

Hz

Hertz

HPLC

high performance liquid chromatography

hr

hour

HR-PKS

highly reducing polyketide synthase

IPTG

isopropyl β-D-1-thiogalactopyranoside

KR

ketoreductase

KS

ketosynthase

L

liter

LB

Luria Bertani

MβL

metallo-β-lactamase

MβL-TE

metallo-β-lactamase-type thioesterase

MES

2-[N-morpholino] ethanesulphonic acid

MGY

minimal glycerol medium

MM

methanol medium

MS

malt soybean medium

MT

methyltransferase

Ni-NTA

nickel-nitrilotriacetic acid

NMR

nuclear magnetic resonance

NR-PKS

non-reducing polyketide synthase

NRRL

Northern Regional Research Laboratory

ORF

open reading frame

PadR

phenolic acid decarboxylase repressor

PASR

phenolic acid stress response

PCR

polymerase chain reaction

xx

PDB

potato dextrose broth

PKS

polyketide synthase

ppm

parts per million

PPtase

phosphopantetheinyl transferase

PT

product template

SARP

Streptomyces antibiotic regulatory protein

SAT

starter unit acyl-carrier protein transacylase

StTS

Streptomyces toxytricini THN synthase

TE

thioesterase

THN

1,3,6,8-tetrahydroxynaphthalene

TpcK

trypacidin decarboxylase

TSB

tryptic soy broth

TSBY

tryptic soy broth-yeast extract

USDA

United States Department of Agriculture

WCW

wet cell weight

YEME

yeast extract-malt extract medium

YM

yeast mold medium

CHAPTER I INTRODUCTION

1.1 Background
Natural products are a major source of bioactive molecules that find applications in agriculture,
nutrition and medicine. Animals, plants and microorganisms are known to produce a large variety
of molecules through precisely programmed biosynthetic pathways. Polyketide compounds
represent a large family of natural products which exhibit diverse biological functions such as
antitumor, anti-inflammatory, antimicrobial, antiviral and anti-cholesterol activities. Polyketides
are synthesized by a group of enzymes called polyketide synthases (PKSs) which are a family of
multi-domain enzymes or enzyme complexes that produce polyketides. Engineering of polyketide
biosynthetic pathways allows the generation of novel compounds that are difficult to be produced
by other methods. PKSs are classified into types I, II and III according to different structures and
mechanisms of these enzymes. Type I PKSs, found in bacteria, fungi, and other organisms, are
giant highly modular enzymes that consist of a series of catalytic domains. Ketosynthase (KS),
acyl transferase (AT), and acyl carrier protein (ACP) are the key domains for polyketide chain
elongation. Some other functional domains, such as starter unit acyl-carrier protein transacylase
(SAT) ketoreductase (KR), enoyl reductase (ER), dehydratase (DH), product template (PT) and
methyltransferase (MT) could be involved according to different polyketide structures [1]. Type
II PKSs are aggregated multienzyme complexes of small discrete enzymes with different monofunctions. These iterative PKS systems are more commonly discovered in prokaryotes, and also
restricted to these organisms. In these systems, a minimal set of iteratively used enzymes, which
are required for assembly of the poly--ketone chain, is called “minimal PKS”. The minimal PKS
is composed of two ketosynthase units KS α, KSβ (chain length factor, CLF) and an ACP. In order
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to define the folding pattern of nascent poly-β-keto intermediate, the polyketide chain synthesized
by the minimal PKS is subjected to further modifications by KR, MT, cyclase (CYC) and
aromatase (ARO). The polyketide backbone is generated by condensation of an acyl starter unit
and multiple malonyl-CoA extender units. [2]. Type III PKSs, long been found in plants, bacteria
and recently in fungi, are single enzymes that form homodimers (40~45 kDa), which contain a
single active site in each monomer to catalyze the priming, extension, and cyclization reactions
iteratively to form polyketide products [3].

Endocrocin (1) and emodin (2) (Fig. 1) are natural anthraquinones noted for their
pharmaceutical applications as laxative, anti-inflammatory, anti-virus, and antitumor agents.
Emodin can also serve as a potential agent in therapy for diabetic nephropathy, liver cirrhosis and
atherosclerosis [4-11]. Besides the pharmaceutic uses, endocrocin and emodin also have industrial
uses as dyes, food additives, components of paper making, and cosmetics [12]. As previously
reported, the endocrocin biosynthetic gene was identified as a special class of type I nonreducing
PKSs (NR-PKSs), named as atrochrysone carboxylic acid synthase (ACAS), that consist of
canonical ketosynthase (KS), acyltransferase (AT), and acyl carrier protein (ACP) domains, but
lack a thioesterase (TE) or Claisen cyclase (CLC) domain [13]. The TE/CLC domain is necessary
for releasing the nascent polyketide product from the enzyme by catalyzing the Claisen cyclization
followed by C-C bond formation and cleavage of the thioester bond between the ACP and the
polyketide backbone [14, 15]. In NR-PKS without TE/CLC domain, the polyketide backbone is
released from the PKS using a group of bifunctional enzymes belonging to the metallo-β-lactamase
(MβL) superfamily that are now termed metallo-β-lactamase-type thioesterases (MβL-TE) [16].
Previous research reported that TpcK from Aspergillus fumigatus serves as a decarboxylase that
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converts endocrocin to emodin. Knockout of tpcK caused significant endocrocin accumulation and
decreased the production of downstream trypacidin pathway metabolites, emodin and questin [17].
Endocrocin is synthesized from eight units of malonyl-CoA [16]. Malonyl-CoA serves as a
common precursor for polyketide biosynthesis. The enzyme acetyl-CoA carboxylase catalyzes the
carboxylation of acetyl-CoA to form malonyl-CoA [18]. Whereas, high level of malonyl-CoA is
required for the biosynthesis of fatty acids, and the production of polyketides competes with native
fatty acid biosynthesis for the available malonyl-CoA during growth. High level production of
polyketides can be quickly limited by malonyl-CoA availability. In Saccharomyces cerevisiae, a
widely used microbial host for heterologous expression, the biosynthesis of cytosolic malonylCoA from acetyl-CoA is carried out by acetyl-CoA carboxylase (acc1). Therefore, to avoid
malonyl-CoA depletion and increase the production of polyketides, the yeast metabolic pathways
have been engineered to increase flux to acetyl-CoA [19-21], and the acc1 gene has been
overexpressed to enhance the supply of malonyl-CoA [22].

Fig. 1 Structures of endocrocin (1) and emodin (2).

Chromomycins, which belong to the family of aureolic acids, are a group of canccrostatic and
antitumor antibiotics synthesized through a type II polyketide biosynthetic pathway in
Streptomyces griseus. They inhibit growth of gram-positive bacteria and also act on multiplication
of several tumor cell lines. Chromomycin A3 (3) (Fig. 2) was reported to stimulate differentiation
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of K562 cell erythroid [23]. This drug was also used as neurological therapeutics [24], and
clinically employed for the treatment of HIV-1 [25], testicular carcinoma and Paget’s disease [26].
A more recent research reported that chromomycin A2 (4) (Fig. 2) induces autophagy in melanoma
cells [27]. Antitumor properties of the antibiotic have been ascribed to its inhibitory role in the
replication and transcription process during macromolecular biosynthesis (26, 28). This antibiotic
interacts, in the presence of Mg2+, with G/C-rich nucleotide sequences located in the minor groove
of DNA. The biosynthetic gene cluster of chromomycin A3 from S. griseus has been identified
and characterized. Thirty six genes were predicted to be involved in polyketide biosynthesis and
modification, deoxysugar biosynthesis and sugar transfer, as well as pathway regulation and
resistance [29]. Besides the genes directly involved in the assembly of the structure of
chromomycins, several regulatory genes were also identified, including streptomyces antibiotic
regulatory protein (SARP) and phenolic acid decarboxylase repressor (PadR) genes, in the gene
cluster, which may have the functions of regulating the expression of the whole gene cluster. In
most cases, the pathway-specific regulator plays a positive role in the transcription of the
biosynthetic genes. The group of proteins referred to as SARPs is prominent among the pathwayspecific regulators in streptomycetes [30]. The PadR gene encodes the transcriptional regulator
that inhibits genes associated with the phenolic acid stress response in some gram-positive bacteria
[31-33]. Among these transcriptional regulatory genes, only a few PadR-like proteins have been
investigated [34-37]
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Fig. 2 Structures of chromomycins A3 (3) and A2 (4).

Spirolaxine (5) (Fig. 3) is a natural product originally discovered from basidiomycetes
Sporotrichum laxum (American Type Culture Collection, ATCC ® 15155) as a plant growth
inhibitor [38]. It was later found to possess significant anti-Helicobacter pylori activity,
representing a potential drug candidate for the treatment of H. pylori-related diseases [39].
Compound 5 was also reported to exhibit cholesterol-lowering activity [40]. A more recent
research reported that 5 has inhibitory activities toward endothelial cells and a variety of tumor
cell lines [41-43]. In order to have a better bioactivity, although there is no sufficient research
related to the biosynthetic pathway of spirolaxine, more and more research was conducted to
synthesize spirolaxine derivatives. Exposure of 5 to Cunninghamella echinulata led to the
hydroxylation on the five-membered ring of the parent structure. The metabolite 8'hydroxyspirolaxine, in comparison to spirolaxine, displayed higher cytotoxic activity towards
bovine microvascular endothelial cells, but reduced the differentiation properties [44]. Spirolaxine
methyl ether, synthesized through chemical reactions, was reported to have anti-H. pylori activity
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[45].

Fig. 3 Structure of spirolaxine (5).

Among the reported PKS heterologous expression systems, E. coli is one of the most widely
used host strains, because it has a relatively mature system for genetic manipulation and high
efficiency for protein expression [46, 47]. This system has been successfully used for the
production of various bioactive molecules. In order to make heterologous host more efficient for
natural products production, many efforts have been put into engineering this bacterium for
increased supply of precursors and co-factors, as well as post-translational modification of the
expressed biosynthetic enzymes. These genetic manipulations have further made E. coli an
attractive heterologous host for natural product biosynthesis. However, it is not well studied how
the endogenous biosynthetic machinery of E. coli affects or interacts with the heterologous
biosynthetic pathway. Recently, our group has identified a new type III PKS StTS from
Streptomyces toxytricini and heterologously expressed it in E. coli BL21(DE3) [48]. This enzyme
uses five units of malonyl-CoA as the substrate to synthesize a polyketide product 1,3,6,8tetrahydroxynaphthalene (THN), which can be spontaneously oxidized to form a red compound
flaviolin (6) (Fig. 4) [49]. This biosynthetic pathway will be used in this work as a model system
to demonstrate the interactions between the endogenous machinery and the heterologous enzyme.
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Fig. 4 Structure of flaviolin (6).

The introduction of heterologous enzymes into a microbial host to generate novel biosynthetic
pathways poses a number of challenges, especially when the native enzymes modify the target
products. Since the flux in central metabolism can be redirected through dynamic control of
enzyme levels, the genetic manipulation is a more commonly used method to control the
expression of the enzymes. However, the modification of culture media or supply of nutrients will
also affect the metabolic flux dramatically in host cells, which will influence the native enzymes
as well as heterologous biosynthetic pathways. My dissertation research provides new insights into
the effects of exogenous substrates on engineered biosynthetic pathways in E. coli and thus affords
a useful approach to creating molecular diversity.

1.2 Objectives
The main goal of my doctoral dissertation research is to identify the biosynthetic pathways of
pharmaceutically valuable polyketide compounds, including those involved in the biosynthesis of
chromomycins (antitumor), spirolaxine (anti-Helicobacter pylori), flaviolin (anti-UV) and emodin
(laxative, anti-inflammatory, and antitumor). Furthermore, I will engineer industrial microbial
strains, such as E. coli, S. cerevisiae and Pichia pastoris, for the ability to efficiently produce these
molecules or generate a series of novel derivatives.
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Specific objectives include:
1. Identify the biosynthetic pathway of emodin and endocrocin, and engineer S. cerevisiae
and P. pastoris to produce these compounds in good yields.
2. Investigate the biosynthetic pathway of chromomycins in S. roseiscleroticus and
increase the production of chromomycins by manipulating the regulatory genes.
3. Investigate the biosynthetic pathways of spirolaxine and flaviolin in E. coli and
generate a series of novel derivatives.

1.3 A guide to the dissertation
This dissertation includes six chapters. Chapter I is a background literature review. Chapter II
focuses on the biosynthetic pathway of emodin from Shiraia sp. strain Slf14 and expressed the
gene cluster in S. cerevisiae and P. pastoris to obtain efficient production of endocrocin and
emodin. Chapter III mainly describes the analysis of the biosynthetic pathway of chromomycins
in S. reseiscleroticus and engineered production of chromomycins by manipulating the regulatory
genes. Chapter IV describes the investigation of the spirolaxine biosynthetic pathway in S. laxum
and heterologous expression of the type III PKS in E. coli. Chapter V describes the supplement of
nutrients links certain intracellular metabolites to the engineered biosynthetic pathway of flaviolin
to yield new products. Chapter VI is a summary of this dissertation and engineering value. A
number of research techniques are used in these studies, including molecular cloning, genetic
engineering, metabolic engineering, microorganism culturing, protein expression, natural products
purification, spectroscopic analyses for structure determination, DNA sequence analysis, aseptic
techniques, laboratory skills, and others. A detailed explanation of each chapter is shown in
following chapters.
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CHAPTER II ENGINEERED PRODUCTION OF ENDOCROCIN AND EMODIN IN YEAST

ABSTRACT
Pharmaceutically valuable anthraquinone compounds endocrocin and emodin were
synthesized by a special class of type I nonreducing polyketide synthases (NR-PKS) and a discrete
metallo-β-lactamase-type thioesterase (TE). We identified a TE-less NR-PKS EmoA and the TE
EmoB from Shiraia sp. strain Slf14 as well as a TE named ACTE1 from Aspergillus candidus.
Heterologous co-expression of EmoA and EmoB in S. cerevisiae BJ5464-NpgA produced
endocrocin and emodin, whereas co-expression of ACTE1 with EmoA will significantly increased
the production of emodin by ~80% and endocrocin by ~45% than the native TE EmoB. To further
improve the production of the target polyketide compounds, we added 1% pyruvate in the medium
to provide more malonly-CoA as substrate, the production titers of emodin and endocrocin were
respectively increased by 14.3% and 13.9%. In order to improve the efficiency of converting
acetyl-CoA to malonyl-CoA, site-directed mutated acetyl-CoA carboxylase (ACC) from S.
cerevisiae, ACC1S1157A, was introduced. The production of endocrocin was increased by ~2-fold,
and emodin increased by ~85%. Since endocrocin can be decarboxylated to form emodin, a
bifunctional enzyme HYP3 was identified and introduced into the S. cerevisiae BJ5464-NpgA
strain. The production of emodin was increased by ~27% and the titer reached 485.4 mg L -1. When
using a decaroboxylase Tpck, the titer of emodin was increased by ~69% and reached 592.5 mg
L-1. Using a similar metabolic engineering approach, we also constructed an engineered P. pastoris
GS115 strain by co-expressing NpgA, EmoA, ACTE1 and TpcK, which resulted in the production
of emodin at 534.8 mg L-1.
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2.1 Introduction
Endocrocin is an natural anthraquinone that was first discovered from the lichen Nephromopsis
endocrocea and later isolated from various fungi [1-4] and higher eukaryotes [5, 6]. Endocrocin
and related anthraquinones, such as emodin, are noted for their medicinal uses as laxative, antiinflammatory, and antitumor agents [6, 7]. Some anthraquinones are also known to be precursors
to mycotoxins, like the aflatoxin intermediates produced by the agricultural fungal pathogens
Aspergillus flavus and Aspergillus parasiticus [8]. Pharmacological studies have demonstrated that
emodin has a variety of bioactivities, such as anti-tumor, anti-viral, anti-inflammatory, and
immune suppression. It can also serve as a potential agent in therapy for diabetic nephropathy,
liver cirrhosis and atherosclerosis [9-14]. With the selective inhibition on the enzyme 11β-HSD1,
which is a key enzyme that catalyzes the intracellular conversion of cortisone to physiologically
active cortisol, emodin has been considered as a potential agent that could reduce the impact of
type 2 diabetes [15]. Besides the pharmaceutic applications, endocrocin and emodin also have
industrial uses as dyes, food additives, components of paper making, and cosmetics [16]. Both
endocrocin and emodin are anthraquinones with 1-, 9-, 11-OH groups and a 3-CH3 group, whereas
endocrocin has an additional 2-carboxyl group.

With more research focused on anthraquinone biosynthesis, the endocrocin biosynthetic gene
was identified as a special class of iterative type I NR-PKSs that consist of SAT, KS, AT, PT and
ACP domains but without a TE or CLC domain [17]. The TE domain, usually located at the Cterminal end of NR-PKS, catalyzes the release of the nascent product from the enzymes by a
Claisen cyclization of the polyketide intermediate, leading to C-C bond formation, accompanied
by cleavage of the thioester bond between ACP and the polyketide backbone [18, 19]. For TE-less

17

NR-PKS, a group of bifunctional enzymes, termed metallo-β-lactamase-type thioesterases (MβLTEs), are required to release the product from the PKS [20]. These MβL-TEs were shown to
catalyze both hydrolysis of the nascent polyketide chain and Claisen cyclization [21, 22].

In this work, we used S. cerevisiae as a host for heterologous expression of the NR-PKS to
produce endocrocin and emodin. This yeast has shown promise for both simple and complex
fungal polyketides such as 6-methylsalisylic acid (6-MSA) and dihydromonacolin L (DML), a
precursor to lovastatin [23-25]. On the other hand, commercial application of the P. pastoris cell
factory is approved by the Food and Drug Administration (FDA) for a variety of recombinant
biopharmaceutical products, such as Kalbitor®, a kallikrein inhibitor [26]. Therefore, we also tried
using P. pastoris as a host to express the NR-PKS and the modifying enzymes in the pathway.
There are some PKSs that were previously reconstituted in P. pastoris. For example, 6-MSA was
efficiently produced in recombinant P. pastoris GS115-NpgA-ATX by co-expressing A. nidulans
phosphopantetheinyl transferase (PPtase) gene npgA and Aspergillus terrus 6-MSA synthase gene
atX [27].

Polyketides are secondary metabolites polymerized from short-chain carboxylic acid units
such as acetate, malonate, propionate, and butyrate [28]. In order to further increase the
productivity in S. cerevisiae, overexpression of acetyl-CoA carboxylase (acc1) can provide more
malonyl-CoA, a common precursor for polyketide biosynthesis. ACC1 catalyzes the carboxylation
of acetyl-CoA to form malonyl-CoA. Acetyl-CoA and malonyl-CoA are also used as precursors
in fatty acid biosynthesis [29]. Fatty acids and polyketides are biosynthesized from multiple units
of building blocks (e.g., malonyl-CoA). Endocrocin and emodin are produced from one molecule
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of acetyl-CoA and seven units of malonyl-CoA [20]. Native yeast strains also require high level
of malonyl-CoA for the biosynthesis of fatty acids, but the foreign polyketides production in S.
cerevisiae competes with native fatty acid biosynthesis for the available malonyl-CoA during
growth. Therefore, production of these polyketides can be quickly limited by malonyl-CoA
availability. The synthesis of cytosolic malonyl-CoA from acetyl-CoA is carried out by ACC1.
Therefore, to avoid malonyl-CoA limitation, the yeast metabolic pathways have been engineered
to increase the flux to acetyl-CoA [30-32] by ACC1 overexpression [33].

According to the previously reported biosynthetic pathway, decarboxylation of endocrocin will
result in the accumulation of downstream pathway metabolites, such as emodin. The
decarboxylase TpcK from A. fumigatus can serve in the decarboxylation of endocrocin. Knockout
of tpcK caused endocrocin accumulation nearly 10-fold and decreased the production of
downstream trypacidin pathway metabolites, emodin and questin [34]. Therefore, to increase the
production of emodin, TpcK was introduced into the heterologous expression system to modify
the biosynthetic pathway. As previously reported, an didomain enzyme CTB3 from the fungal
plant pathogen Cercospora nicotianae, with an O-methyltransferase domain and a flavindependent monooxygenase domain, serves as decarboxylase in the decarboxylation of nortoralactone [35]. As shown in Fig. 5, we identified a bifunctional enzyme HYP3 from Shiraia sp.
strain Slf14, which is a homolog of CTB3 (46.52% identity). We found that HYP3 can also work
in the decarboxylation of endocrocin to form emodin.
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Fig. 5 Amino acid sequence alignment of CTB3 and HYP3.

2.2 Materials and methods

2.2.1 General method
Polyketide products were detected and isolated on an Agilent 1200 high performance liquid
chromatography (HPLC) instrument. Electrospray ionization mass spectrometry (ESI-MS) spectra
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were collected on an Agilent 6130 Single quadrupole LC-MS. Nuclear magnetic resonance (NMR)
spectra were acquired in DMSO-d6 on a Bruker NMR instrument (500 MHz for 1H NMR and 125
MHz for

13C

NMR). The chemical shift (δ) values were given in parts per million (ppm). The

coupling constants (J values) were reported in Hertz (Hz).

2.2.2 Strains and materials
Shiraia sp. strain Slf14 (China Center for Type Culture Collection [CCTCC] no. 209294) was
obtained from Dr. Du Zhu at Jiangxi Normal University, Nanchang, China. The strain was cultured
in potato dextrose broth (PDB) medium. A. candidus, maintained in PDB medium, was obtained
from Agriculture Research Service Culture Collection (NRRL No. 5214). DNA manipulations
were performed using standard techniques with E. coli XL1-Blue (Agilent) as a host organism and
pJET1.2 for cloning (Thermo Scientific, USA). E. coli cells were grown in Luria-Bertani (LB)
medium, and 50 μg mL-1 ampicillin was added when necessary. S. cerevisiae BJ5464-NpgA was
obtained from Dr. Nancy Da Silva at the University of California, Irvine. The strain was
maintained on YPD (1% yeast extract, 2% peptone, 2% dextrose) agar plates at 30C. The E. coliS. cerevisiae shuttle vectors pRS423 was purchased from ATCC, pRS425-OMT and
pXW55/pXW06 were gifts from Dr. Istvan Molnar at the University of Arizona and Dr. Yi Tang
at the University of California, Los Angeles, respectively. pSUN38, which was used to express
EmoA or HYP1, was derived from pXW55. Pichia pastoris GS115, pPICZB and pPIC3.5K were
commonly used strain and vectors in our lab.

2.2.3 Extraction and analysis of genomic DNA
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A. candidus NRRL 5214 was cultured in 50 mL of potato dextrose broth (PDB) at 28 C for 4
days, and the genomic DNA was extracted using the reported method [36]. The genome was then
sequenced using an Illumina MiSeq desktop sequencer and assembled with the short read de novo
assembler Velvet. With the sequence reported, we used Augustus for gene prediction [37], and
BLASTX for annotation. FramePlot [38] was used to analyze the predicted PKS genes, with A.
oryzae transcriptome as the reference. The genome of Shiraia sp. strain Slf14 was reported by Dr.
Du Zhu’s group [39].

2.2.4 Amplification of intron-free genes and construction of heterologous expression plasmids
Wild type Shiraia sp. strain Slf14 was grown in PDB at 28 C for 3 days. The cells were
harvested by filtration, from which the RNA was extracted with TRIzol Reagent (Invitrogen, USA).
The extracted RNA was purified with a Direct-zol RNA MiniPrep kit (Zymo Research, CA, USA).
The cDNA was synthesized from total RNA with M-MuLV Reverse Transcriptase (NEB, MA,
USA). With the cDNA as a template, a 5,400-bp DNA fragment of the intron-free emoA gene was
amplified by PCR with a set of specific primers including JNU-1-nrPKS-SpeI-F and JUN-1nrPKS-PmeI-R (Table 1). The resulting intron-free fragment was cloned into the pJET1.2 cloning
vector, and subsequently cloned into pSUN38 vector between the SpeI and PmeI sites, resulting in
pSUN39. A 1,002-bp DNA fragment of intron-free emoB gene was amplified by PCR with a set
of specific primers including JUN-1-TE-NdeI-5 and JUN-1-TE-PmeI-3 (Table 1). The resulting
fragment was cloned into the pJET1.2 cloning vector, and subsequently cloned into pXW06 vector,
between the NdeI and PmeI sites, resulting in pSUN64. A 6504-bp DNA fragment of intron-free
hyp1 gene was amplified by PCR with a set of specific primers including JNU1-40-PKS-5-PmeI
and JNU1-40-PKS-3-PmlI (Table 1). The resulting fragment was cloned into the pJET1.2 cloning
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vector, and subsequently cloned into pSUN38 vector between the PmlI and PmeI sites, resulting
in pSUN102. Another primer set of JNU1-40-PKS-5-PmeI and JNU1_40_PKS_no_TE_3_PmlI
was used to amplify the hyp1-te gene. The resulting 5724-bp fragment was cloned into the
pJET1.2 cloning vector, and subsequently cloned into pSUN38 vector, between the PmlI and PmeI
sites, resulting in pSUN126. Then the 1,008-bp fragment of tehyp1 gene with linker was amplified
by PCR with a set of specific primers including JNU1_40_PKS_TE_5_NdeI and
JNU1_40_PKS_TE_3_PmeI (Table 1). The resulting fragment was cloned into the pJET1.2
cloning vector, and subsequently cloned into pXW06 vector, between the NdeI and PmeI sites,
resulting in pSUN121. A 2823-bp DNA fragment of intron-free hyp3 gene was amplified by PCR
with a set of specific primers including JNU1-40-dualMT-5-NdeI and JNU1-40-dualMT-3-PmeI
(Table 1). The resulting fragment was cloned into the pJET1.2 cloning vector, and subsequently
cloned into the pRS425-OMT vector, between the NdeI and PmeI sites, resulting in pSUN108.
Wild type A. candidus NRRL 5214 was grown in PDB medium at 28 C for 7 days. The RNA
extraction and cDNA synthesis strategy is described as above. Using the cDNA as the template, a
957-bp DNA fragment of intron-free acte1 gene was amplified by PCR with a set of specific
primers including 5214_S7_TE_NdeI_F and 5214_S7_TE_PmeI_R (Table 1). The resulting
fragment was cloned into pJET1.2, and subsequently cloned into the pXW06 vector, between the
NdeI and PmeI sites, resulting in pSUN143. The S. cerevisiae BJ5464-NpgA was grown in YPD
broth at 28 C for 2 days. And the genomic DNA was extracted using a ZR Fungal/Bacterial DNA
MiniPrep kit (Zymo Research, CA, USA). With the genomic DNA as the template, a 6,702-bp
DNA fragment of acc1 gene was amplified by PCR with a set of specific primers including
ACC_NdeI_F and ACC_PmeI_R (Table 1). The resulting fragment was cloned into pJET1.2, and
subsequently cloned into the pRS425-OMT vector between the NdeI and PmeI sites, yielding
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pSUN147.

The

ACC1

gene

was

mutated

using

primers

ACC1_S1157A_SDM_F,

ACC1_S1157A_SDM_R to change the serine 1157 residue to alanine. The acc1S1157A gene was
cloned into pJET1.2, and subsequently cloned into pRS425-OMT vector between the NdeI and
PmeI sites, resulting in pSUN164. The PAdh2-acc1S1157A-TAdh2 cassette was then cloned into the
pRS423 vector between SacII and NotI sites, yielding pSUN169.

Table 1. List of primers used in Chapter II. *
Primers
JNU-1-nrPKS-SpeI-F
JUN-1-nrPKS-PmeI-R
JUN-1-TE-NdeI-5
JUN-1-TE-PmeI-3
JNU1-40-PKS-5-PmeI
JNU1_40_PKS_no_TE_3_PmlI
JNU1-40-PKS-3-PmlI
JNU1_40_PKS_TE_5_NdeI
JNU1_40_PKS_TE_3_PmeI
5214_S7_TE_NdeI_F
5214_S7_TE_PmeI_R
JNU1-40-dualMT-5-NdeI
JNU1-40-dualMT-3-PmeI
ACC_NdeI_F
ACC_PmeI_R
ACC_AscI_F
ACC1_S1157A_SDM_F
ACC1_S1157A_SDM_R
NpgA_SnaBI_F
NpgA_NotI_R
AOX1F
AOX1R

Sequence
5'-AAACTAGTATGAAGGTCATCTACTTCGG-3'
5'-GGGTTTAAACTTAACCGTGATACTCCTCCA-3'
5'-CCCATATGATGGCTCCACATGCCAACTC-3'
5'-GGGTTTAAACTTACATGATGGCATACCATT-3'
5'-GGGTTTAAACATGGCGGAGCCCATCAAGGT-3'
5'-GCACGTGCAGTTTCTCCCTTGCGTTTCG-3'
5'-AACACGTGTCAAACAACCAACCCTAGAG-3'
5'-GCATATGGGAGCTCGCCAATCG-3'
5'-GGTTTAAACTCAAACAACCAACCCTAGAG-3'
5'-AACATATGAGTAAAGGAGGGTACCAACAG-3'
5'-AAGTTTAAACTCACTCCAACGCCCCAAC-3'
5'-AACATATGGCTACGTCAACCTCTTT-3'
5'-AAGTTTAAACTCAGTCCGACACAACCGCCA-3'
5'-CCCATATGAGCGAAGAAAGCTTATTCG-3'
5'-GGTTTAAACTTATTTCAAAGTCTTCAACAATTTTTC-3'
5'-AGGCGCGCCATGAGCGAAGAAAGCTTATTCG-3'
5'-GGGTATGAACAGGGCTGTTGCTGTTTCAGATTTGTC-3'
5'-GACAAATCTGAAACAGCAACAGCCCTGTTCATACCC-3'
5'-GGAATTCTACGTAACCATGGTGCAAGACACATCAAGCGCAAG-3'
5'-GAATGCGGCCGCTTAGGATAGGCAATTACACACCC-3'
5'-AGATCTAACATCCAAAGACG-3'
5'-GCACAAACGAAGGTCTC-3'

Sites
SpeI
PmeI
NdeI
PmeI
PmeI
PmlI
PmlI
NdeI
PmeI
NdeI
PmeI
NdeI
PmeI
NdeI
PmeI
AscI

SnaBI
NotI

*The restriction sites are underlined.

For the expression in P. pastoris GS115, with the S. cerevisiae BJ5464-NpgA genomic DNA as
the template, a 1,038-bp DNA fragment of npgA gene was amplified by PCR with a set of specific
primers including NpgA_SnaBI_F and NpgA_NotI_R (Table 1). The resulting fragment was
cloned into pJET1.2, and subsequently cloned into pPIC3.5K vector between the SnaBI and NotI
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sites, yielding pSUN199. The emoA gene was cloned into pPICZB vector between NdeI and AscI
sites, resulting in pSUN201, which was linearized with PmeI before transformed into GS115,
yielding PG-S201. The TpcK gene with restriction sites (451 bp) was synthesized by General
Biosystems, Inc. (NC, USA) and was cloned into pRS425-OMT (NdeI/PmeI) and pPIC3.5K
(NdeI/NotI), respectively, resulting into the construction of pSUN207 and pSUN221. The ACTE1
gene was also cloned into pPIC3.5K between NdeI and AscI to yield pSUN222. With pSUN221
and pSUN222 as the templates, the primers AOX1F and AOX1R were used to amplify the PAOX1tpcK-TAOX1 cassette and the PAOX1-acte1-TAOX1 cassette, then cloned into pJET1.2 to yield
pSUN223 and pSUN224, respectively. The PAOX1-tpcK-TAOX1 cassette was subsequently cloned
into pSUN199 in the BglII site, yielding pSUN225. The PAOX1-acte1-TAOX1 cassette was cloned
into pSUN225 in the BglII site, yielding pSUN227. The expression of genes npgA, tpcK and acte1
in pSUN227 were under the control of independent AOX1 promoter and terminator. pSUN227
was linearized with SalI before transformed into the strain PG-S201, yielding PG-S201S227. All
the strains and plasmids are listed in table 2.
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Table 2 List of strains and plasmids used in Chapter II.
Strains

Genotype

Saccharomyces cerevisiae BJ5464-NpgA
Pichia pastoris GS115
PG-S201
PG-S201S227
Shiraia sp. Slf14
Aspergillus candidus NRRL5214

MATα ura3-52 his3-Δ200 leu2-Δ1 trp1 pep4::HIS3 prb1 Δ1.6R can1 GAL
His4 Mut+
Pichia pastoris GS115/ emoA
Pichia pastoris GS115/ npgA-tpcK-emoA-acte1
WT
WT

Plasmids
pSUN33
pSUN34
pSUN38
pSUN39
pSUN64
pSUN96
pSUN98
pSUN102
pSUN108
pSUN118
pSUN121
pSUN123

Description
emoA in pJET1.2
emoA in pJET1.2
pXW55 added restriction sites NdeI, PmeI, SpeI
emoA in pSUN38
emoB in pXW06
hyp3 in pJET1.2
hyp1 in pJET1.2
hyp1 in pSUN38
hyp3 in pRS425-OMT
tehyp1 in pJET1.2
tehyp1 in pXW06
hyp1-te in pJET1.2

pSUN126
pRY06
pSUN143
pSUN144
pSUN147
pSUN156
pSUN164
pSUN169
pSUN196
pSUN199
pSUN201
pSUN207
pSUN221
pSUN222
pSUN223
pSUN224
pSUN225
pSUN227

hyp1-te in pSUN38
acte1 in pJET1.2
acte1 in pXW06
acc1 in pJET1.2
acc1 in pRS425-OMT
acc1S1157A in pJET1.2
acc1S1157A in pRS425-OMT
PAdh2-acc1S1157A-TAdh2 in pRS423
npgA in pJET1.2
npgA in pPIC3.5K
emoA in pPICZB
tpcK in pRS425-OMT
tpcK in pPIC3.5K
acte1 in pPIC3.5K
PAOX1-tpcK-TAOX1 in pJET 1.2
PAOX1-acte1-TAOX1 in pJET 1.2
tpcK-npgA in pPIC3.5K
acte1-tpcK-npgA in pPIC3.5K

2.2.5 Transformation and fermentation of P. pastoris GS115
The electrotransformation of P. pastoris GS115 was performed using MicroPulser TM (BioRad)
using the previously reported method [40].
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The single colony of P. pastoris GS115-npgA-tpcK-emoA-acte1 was inoculated into MGY
medium (glycerol 10 g L-1, yeast nitrogen base 6.7 g L-1, biotin 0.4 mg L-1) as seed culture and
cultivated at 30 °C and 250 rpm for 24 hr. Then 1 mL of seed culture was transferred into 50 mL
of MGY medium to cultivate at 30 °C and 250 rpm for an additional 18 hr. The liquid was
centrifuged at 3,000 g for 5 min, washed with 10 mL of MM medium (yeast nitrogen base 13.4 g
L-1, biotin 0.4 mg L-1) twice and suspended with MM medium to be OD600 1.0. Afterwards, 50 mL
of broth was transferred into a 500-mL baffled shake flask, covered with two layers of gauze and
cultivated at 30 °C and 250 rpm. Methanol was fed every 24 hr to keep its concentration around
1.0% to induce protein expression and provide carbon source as substrate to produce polyketide
products.
For the expression in 5-L bioreactor, 100 mL of seed culture (OD 600 = 6.0) in MGY medium
were collected and inoculated into a 5-L stirred-tank New Brunswick™ BioFlo®/CelliGen®115
bioreactor (Eppendorf) containing 3 L of MM medium. The cultivation conditions are same as
described before [27].

2.2.6 Transformation and fermentation of S. cerevisiae BJ5464-NpgA
Transformation of plasmid pSUN39 or pSUN102 and co-transformation of pSUN64,
pSUN108, pSUN121, pSUN126, pSUN143, pSUN147, pSUN164, pSUN169 and pSUN207, in
different groups, into S. cerevisiae BJ5464-NpgA competent cells. Selection of correct
transformants was performed as previously described [41]. The engineered S. cerevisiae BJ5464NpgA strain carrying pSUN39 or pSUN102 was fermented in a SC-Ura dropout medium (6.7 g L1

yeast nitrogen base; 20 g L-1 glucose; 0.77 g L-1 -Ura DO supplement) at 30 °C and 250 rpm until

the OD600 reached 1.0, and then added 10 g L-1 yeast extract and 20 g L-1 Bacto peptone. The
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cultures were cultivated under the same conditions for an additional 72 hr to produce the polyketide
products.

S.

cerevisiae

pSUN39+pSUN143,

BJ5464-NpgA

pSUN39+pSUN121,

harboring

two

plasmids

pSUN126+pSUN121,

pSUN39+pSUN64,

pSUN126+pSUN64

or

pSUN126+pSUN143 was fermented in a SC-Ura-Trp dropout medium (6.7 g L-1 yeast nitrogen
base, 20 g L-1 glucose, 0.72 g L-1 -Trp/-Ura DO supplement) at 30 °C and 250 rpm until the OD600
reached 1.0, and then an equal volume of YP medium was added. The fermentation broths were
cultured under the same conditions for an additional 72 hr to produce the polyketide products. S.
cerevisiae BJ5464-NpgA harboring three plasmids pSUN39, pSUN64 and pSUN147; pSUN39,
pSUN143 and pSUN147; pSUN39, pSUN64 and pSUN164; or pSUN39, pSUN143 and pSUN164
was fermented in a SC-Ura-Trp-Leu dropout medium (6.7 g L-1 yeast nitrogen base; 20 g L -1
glucose; 0.62 g L-1 -Trp/-Ura/-Leu DO supplement) at 30 °C and 250 rpm until the OD600 reached
1.0, and then an equal volume of YP medium. The fermentation broths were cultured under the
same conditions for an additional 72 hr to produce the polyketide products. S. cerevisiae BJ5464NpgA

harboring

four

plasmids

pSUN39+pSUN108+pSUN143+pSUN169

or

pSUN39+pSUN143+pSUN169+pSUN207 was fermented in a SC-Ura-Trp-Leu-His dropout
medium (6.7 g L-1 yeast nitrogen base, 20 g L-1 glucose, 0.60 g L-1 -Trp/-Ura/-Leu/-His DO
supplement) at 30 °C and 250 rpm. When the OD 600 reached 1.0, 10 g L-1 yeast extract and 20 g
L-1 Bacto peptone were added. The fermentation broths were cultured under the same conditions
for an additional 72 hr to synthesize the polyketide products.

2.2.7 Polyketide biosynthesis
S. cerevisiae BJ5464-NpgA cells harboring expression vectors were grown under the same
conditions as described before. The broth was maintained at 28 °C and 250 rpm for an additional
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7 days. The cells were harvested by centrifugation at 3,500 rpm for 5 min. For time course analysis,
every 24 hr, polyketide products were extracted from broth with ethyl acetate and the pellet with
methanol. The cell and supernatant extracts were combined and concentrated using a rotavapor.
The cells of P. pastoris GS115-npgA-tpcK-emoA-acte1 were harvested by centrifugation at 3,500
rpm for 5 min. The broth was extracted with ethyl acetate and the pellet with methanol, then
concentrated by a rotavapor. The extracts were analyzed on an Agilent 1200 HPLC instrument
(Agilent Eclipse Plus C18, 5 μm, 4.6 mm × 250 mm), eluted with a linear gradient of 10 to 90 %
(v/v) acetonitrile-water (containing 0.1% trifluoroacetic acid) over 45 min at a flow rate of 1 mL
min−1. The products were detected at 420 nm. For quantification of compounds 1, 2 and 7, we
purified the compounds according to the method described in 2.2.8, and established the standard
curves based on the target peak area of UV absorption at 420 nm over the weight (µg) of the
compound, for the three compounds respectively. The standard curves for 1, 2 and 7 were y =
74808x + 548.14 (R² = 0.9939), y = 645.17x + 568.39 (R² = 0.9991), and y = 4930.4x + 70.873
(R² = 0.9933), respectively.

2.2.8 Purification and structural characterization of compounds 1, 2, 7 and 8
To isolate three main compounds 1, 2, and 7 for structural characterization, the culture was
scaled up to 1 L and grown for 5 days. Briefly, 1 mL of seed culture (OD 600=1.0) of S. cerevisiae
BJ5464-NpgA cells harboring pSUN39 and pSUN64 was inoculated into 1 L of broth and cultured
under the same conditions as described in 2.2.6. After fermentation, the culture was extracted. To
isolate these compounds, a typical purification procedure was given below. The crude extract was
fractionated on a silica gel-60 column, eluted with a stepwise gradient of methanol-chloroform
(0:100, 1:99, 2:98, 3:97, 5:95, 10:90, 15:85, v/v, each 250 mL) to afford 7 fractions. The fractions
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containing the target compounds were further separated by reverse-phased HPLC (Agilent Eclipse
Plus C18, 5 μm, 4.6 mm × 250 mm), eluted with acetonitrile-water at a flow rate of 1 mL min−1.
Compound 2 was found to be in fraction 3 after silica gel column chromatography. This fraction
was further separated on HPLC with 44% acetonitrile/water. The peak at 24.9 min was collected
to yield 7.9 mg of 3 in a pure form. Compounds 1 and 7 were found to be in fraction 4 after silica
gel column chromatography. This fraction was further separated on HPLC with 34%
acetonitrile/water. The peaks at 15.7 min and 22.1 min were collected to yield 5.6 mg of 1 and 7.3
mg of 7, respectively, in a pure form. For isolation of compound 8, the culture of S. cerevisiae
BJ5464-NpgA cells harboring pSUN102 and the extraction of culture were described as above.
The crude extract was also fractionated on a silica gel-60 column as described above. Compound
8 was found to be in fraction 3 after silica gel column chromatography. This fraction was further
separated on HPLC with 38% acetonitrile/water. The peak at 23.7 min was collected to yield 6.8
mg of 8 in a pure form.

2.3 Results

2.3.1 Discovery and analysis of three putative iterative type I polyketide synthases
The genomic sequence of Shiraia sp. strain Slf14 was reported before [39]. A total of 12,513
proteins were predicted by Augustus, which are annotated by comparing with the NCBI
nonredundant (NR) protein databases with BLASTX. The sequence data were further analyzed by
using a gene annotation tool FramePlot with A. oryzae transcriptome as the reference. A TE-less
type I NR-PKS and the adjacent β-lactamase-type TE, emoA and emoB, are arranged in the same
transcriptional direction on the genome, separated by a region of ~8.0 kb (Fig. 6 A i). BLAST
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analysis of the primary amino acid sequences of the deduced proteins yielded many homologs of
PKSs. The closest homolog to EmoA is a putative PKS (KNG44542.1, 83% identity) and EmoB
is homologous to a putative metallo-β-lactamase domain-containing protein (KNG44536.1, 88%
identity) from Stemphylium lycopersici. The genome of Aspergillus candidus (NRRL No. 5214)
was sequenced and gene prediction was performed according to the same strategy described above.
Using A. nidulans transcriptome as reference, 8,711 proteins were predicted. One putative iterative
type I NR-PKS gene and a β-lactamase-type TE gene, acpks and acte1, were arranged tail to tail
on the genome, separated only by a region of ~0.5 kb (Fig. 6 A ii). Similar to EmoA and EmoB,
BLAST analysis also showed that some PKSs (XP_001266594.1, 66% identity) and metallo-βlactamase domain-containing protein (KUI53802.1, 71% identity) genes have high homology to
ACPKS and ACTE1. A 6,504-bp iterative type I NR-PKS gene (hyp1) was annotated before
(AIW00658.1) with FramePlot analysis. The ACP domain ends at 5,496 bp and the TE domain
starts at 5,724 bp and ends at 6,504 bp. The DNA sequence between the ACP and TE domain was
considered as a linker that may play a role in the crosstalk between different domains. Therefore,
we proposed the length of the fully functional TE domain (tehyp1) of hyp1 is 1,008 bp (Fig. 6 A iii).
As shown in Fig. 6 B, sequences alignment of TEHYP1, EmoB, ACTE1 with Aspergillus terreus
ATEG_08451 [20] revealed that EmoB, ACTE1 and ATEG_08451 have a relatively higher
homology of 70.05%, while the similarity to TEHYP1 is quite low (~10%).
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Fig. 6 Different type I NR-PKSs and sequence alignment of related TEs. (A) The gene cluster loci
of emoA (i), acpks (ii), and the domain organization of HYP1 (iii). (B) Sequence alignment of
EmoB, ACTE1, ATEG_08450 and TEHYP1. The same amino acids are shaded in black, and similar
ones are in grey. The conserved hydrolytic activities catalytic triad is asterisked.

2.3.2 Characterization of the products synthesized by NR-PKSs in S. cerevisiae
In order to understand the functions of EmoA and EmoB in polyketide biosynthesis. We
constructed expression plasmids pSUN38-emoA and pXW06-emoB. The expression was
controlled by the Adh2 promoter, which will be activated after glucose exhausted in the medium.
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After 7 days of growth, the broth culture was extracted and concentrated, and HPLC was used to
analyze the samples at 420 nm. As shown in trace i of Fig. 7 A, the blank control did not produce
any target polyketide products. Same as the blank control, EmoA alone gave no products in the
yeast either (trace ii, Fig. 7 A). Because EmoA lacks a C-terminal TE domain, which is in charge
of releasing the polyketide products from the enzyme, we proposed that the polyketide
intermediate remained attached to the ACP domain and thus no products were observed. Then we
tried co-expressing EmoA with EmoB, which are presented in the same gene cluster in Shiraia sp.
strain Slf14. Three main compounds were detected by HPLC at the retention time of 17.8 (7), 20.4
(1) and 30.7 (2) min, respectively (trace iii, Fig. 7 A). After confirming that EmoA can work with
EmoB to form the polyketide products, we further examined whether EmoA can recognize the TE
from another strain (ACTE1) or the TE domain (TEHYP1) isolated from a naturally integrated NRPKS system. As shown in trace iv of Figure 7 A, EmoA gave no products when co-expressed with
TEHYP1 that was isolated from HYP1. By contrast, ACTE1 can be accepted by EmoA to form the
same products (trace v, Fig. 7 A). In order to identify compounds 1, 2 and 7, a scaled up broth
was prepared. ESI-MS analysis of 1 showed ion peaks [M+H]+ at m/z 315 and [2M+H]+ m/z 629,
indicating that the molecular weight of this compound is 314, which corresponds to that of
endocrocin. The 1H NMR (Table 3) of 1 indicated that the compound has three aromatic proton
signals and a high field methyl group signal. Sixteen carbons were observed in the

13C

NMR

spectrum (Table 4) of 1. The molecular weight of 7 was determined to be 274 on the basis of the
[M+H]+ peak at m/z 275 and [2M+H]+ peak at m/z 549 in the ESI-MS spectrum. The 1H (Table 3)
and

13C

(Table 4) NMR data indicated that 7 has three aromatic protons, a methyl group, and a

total of fifteen carbons. The ESI-MS of 2 revealed the [M+H]+ ion peak at m/z 271, indicating that
the molecular weight is 270, which is 44 mass units less than 1. The 1H (Table 3) and 13C (Table
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4) NMR data showed that 2 has four aromatic protons, a methyl group and a total of fifteen carbons.
By comparing the 1H (Table 3) and 13C (Table 4) NMR spectra with the reported data [41, 42], 1
was identified as endocrocin, 7 was identified as atrochrysone, and 2 was identified as emodin
(Fig. 7 C).

We next investigated whether the TE-less HYP1 can recognize the TEs from other origins. A
PCR mediated mutation was performed to remove the TE domain of HYP1, and the gene fragment
of hyp1te was ligated into the expression vector pSUN38. As shown in trace i, Fig. 7 B, the
empty vector is the negative control, and the native HYP1 that produced compound 8 eluted at the
retention time of 25.6 min (trace vi, Figure 7 B) served as a positive control. However, coexpression of HYP1TE with the two β-lactamase-type TEs, EmoB or ACTE1, did not give any
target products (traces ii and iii, Figure 7 B). By contrast, co-expression of HYP1TE with its
original TE domain TEHYP1 in the yeast reconstituted the biosynthesis of 8 (trace iv, Figure 7 B),
which showed that the separated TEHYP1 can be recognized by HYP1TE and was fully
functional. In order to identify 8, a scale up broth was prepared, and 8 was purified. The molecular
weight of 8 was determined to be 258 based on the [M+H]+ ion peak at m/z 259 in the ESI-MS
spectra. The 1H (Table 3) and

13C

(Table 4) NMR data showed 8 has four aromatic protons, a

methyl group, and a total of fourteen carbons. By comparing its 1H (Table 3) and 13C (Table 4)
NMR spectra with the reported data [43], 8 (m/z 259 [M+H]+) was identified as nor-toralactone
(Fig. 7 C).
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Fig. 7 Analysis and structures of the products of S. cerevisiae BJ5464-NpgA harboring different
plasmids. (A) HPLC analysis (detected at 420 nm) of products of S. cerevisiae BJ5464-NpgA
harboring different plasmids: empty vectors (i), pSUN39 (ii), pSUN39 and pSUN121 (iii),
pSUN39 and pSUN64 (iv), pSUN39 and pSUN143 (v). (B) HPLC analysis (detected at 420 nm)
of products of S. cerevisiae BJ5464-NpgA harboring different plasmids: empty vectors (i),
pSUN126 and pSUN143 (ii), pSUN126 and pSUN64 (iii), pSUN126 and pSUN121 (iv), pSUN126
(v) and pSUN102 (vi). (C) Structures of endocrocin (1), emodin (2), atrochrysone (7) and nortoralactone (8).
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Table 3 1H-NMR (500 MHz) data for 1, 2, 7 and 8 (DMSO-d6).
Position
2
4
6
8
10
15
1’
3’
1-OH
7-OH
9-OH
11-OH
13-OH

1H-NMR,

δ, ppm (area, m, J in Hz)

1
7.49 (1H, s)
7.10 (1H, d, 2.4)
6.59 (1H, d, 2.4)
2.41 (3H, s)

7
2.87 (2H, s)
2.91 (2H, s)
6.78 (1H, s)
6.48 (1H, d, 2.4)
6.30 (1H, d, 2.4)
1.27 (3H,s)

2
7.20 (1H, s)
7.52 (1H, s)
7.15 (1H, d, 2.4)
6.62 (1H, d, 2.4)
2.43 (3H, s)

8
6.95 (1H, s)
6.56 (1H, d, 2.4)
6.40 (1H, d, 2.4)

6.42 (1H, s)
2.20 (3H, s)
12.04 (1H, s)
10.24 (1H, s)
12.15 (1H, s)
12.73 (1H, brs)

12.19 (1H, s)
10.26 (1H, brs)
12.34 (1H, s)

12.11 (1H, s)
11.41 (1H, s)

Table 4 13C-NMR (125 MHz) data for 1, 2, 7 and 8 (DMSO-d6, δ in ppm, J in Hz).
Position
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1'
2'
3'
4'

13C-NMR

1
159.5
130.1
143.9
120.3
134.9
181.2
132.6
108.7
165.5
108.1
164.5
109.2
189.2
114.1
20.4
167.3

7
203.1
50.6
69.5
42.5
137.1
116.1
141.1
101.1
161.4
101.8
159.3
106.2
165.5
107.8
28.9

2
161.9
124.7
148.8
120.9
135.6
181.9
133.4
109.3
165.6
108.5
166.1
109.1
190.3
113.8
22.3

2.3.3 Optimization of polyketide production in S. cerevisiae

8
163.3
97.2
132.2
111.5
142.2
101.9
161.4
102.1
159.1
107.6

104.7
152.8
19.3
167.2
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Endocrocin (1), emodin (2) and atrochrysone (7) all have potential pharmaceutical values. In
order to optimize the production of these compounds, we conducted a time course analysis.
Samples were collected every day and analyzed using HPLC at 420 nm. As shown in Fig. 8 A,
atrochrysone (7) was synthesized and the highest titer (109.3±15.9 mg L-1) was reached after 4
days. The production of 7 rapidly decreased after 5 days and became undetectable in the 7-days’
culture. The titers of endocrocin (1) and emodin (2) were gradually increased to the highest titers
(134.5±13.9 and 97.0±11.3 mg L-1, respectively) in the 7-day’s culture. In order to check the
differences between the two TEs in polyketide biosynthesis, we also cultured S. cerevisiae BJ5464NpgA/emoA-acte1. Interestingly, although 1, 7 and 2 were produced in a similar pattern as S.
cerevisiae BJ5464-NpgA/emoA-emoB did, ACTE1 revealed a higher efficiency in polyketide
biosynthesis. Compared to the extracts of S. cerevisiae BJ5464-NpgA/emoA-emoB, the titers of 1,
7 and 2 in extracts of S. cerevisiae BJ5464-NpgA/emoA-acte1 were 46.2%, 65.1% and 62.9%
higher, respectively (Fig. 8 B). According to previous research, the atrochrysone carboxyl ACP
thioesterase (ACTE) catalyzed the hydrolysis of the thioester bond between the ACP domain of
atrochrysone carboxylic acid synthase (ACAS) and the octaketide intermediate, releasing the
atrochrysone carboxylic acid as the product [20]. This result reveals that, when working with
EmoA, ACTE1 has a much higher hydrolysis activity or releasing efficiency than the native EmoB.
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Fig. 8 The production of 1, 2 and 7 in the yeast. (A) Time course analysis of 1, 2 and 7 productions
in S. cerevisiae BJ5464-NpgA/pSUN39+pSUN64. (B) Time course analysis of 1, 2 and 7
productions in S. cerevisiae BJ5464-NpgA/pSUN39+pSUN143. (C) Quantitative analysis of the
production of compounds 1, 2 and 7. S. cerevisiae BJ5464-NpgA/pSUN39+pSUN143 in YPD
medium with different carbon sources. For 7, samples were collected in the 4-days’ culture, and
for 1 and 2, samples were harvested in the 7-days’ culture.

In order to optimize the production, we attempted to increase the supply of carbon source in
the medium. Since the expression plasmid has the Adh2 promoter, which is inhibited by the
presence of glucose, we chose pyruvate, fructose and glycerol as the extra carbon sources for the
production of 1, 2 and 7. The SC medium (0.67% yeast nitrogen base, 2% glucose, -Ura-Trp
dropout supplement) was used as the start medium to culture cells for 24 hr, then 1% yeast extracts
and 2% peptone were added. After another 24-hr’s culture, extra 1% corresponding carbon source
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(pyruvate, fructose or glycerol) was added respectively to provide more acetate or malonate as
precursor for polyketide synthesis, the empty control labeled as YPD (Fig. 8 C). According to the
results shown above, the highest production of 7 was detected in 4-days’ culture, and the
production of 1 and 2 reached a stable level after 7 days. We thus extracted the 4-days’ broth to
record the production data of 7, and 7-days’ broth for 1 and 2. As shown in Fig. 8 C, compared to
the empty control, supplement of pyruvate increased the production of polyketides 1 by13.8%, 7
by 32.6%, and 2 by 14.7%, whereas the other two carbon sources only slightly increased the titers
(average ~2.5%).
In order to further improve the production of 1, 2, and 7, we introduced another plasmid
containing the S. cerevisiae acetyl-CoA carboxylase gene acc1 to co-express with emoA and acte1.
Acetyl-CoA is produced during breakdown of carbohydrates through glycolysis as well as
breakdown of fatty acids through β-oxidation. Previous research discovered that ACC1 facilitates
the conversion of acetyl-CoA to malonyl-CoA, thus overexpression of the acc1 gene increases the
accumulation of malonyl-CoA [30-32]. Therefore, we transformed S. cerevisiae BJ5464-NpgA
with three plasmids containing emoA, acte1 and acc1, respectively, and using the empty vectors
as the negative control. The results showed that engineered strains of emoA-emoB-acc1 and emoAacte1-acc1 both yielded 1, 2, and 7 (trace ii, iii, Fig. 9 A). Co-expression of EmoA with site-direct
mutated ACC1S1157A and ACTE1 yielded 1, 2, and 7 as well, while the negative control did not
give any target products (trace i, Fig. 9 A). The polyketide titers with different sets of enzymes
were recorded (Fig. 9 B). Compared to EmoA and ACTE1 co-expression, introduction of ACC1
into S. cerevisiae BJ5464-NpgA significantly increased the production of 1 by 38.6%, 7 by 41.2%,
and 2 by 47.2%.
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Fig. 9. The effect of site-directed mutagenesis of ACC1 on the production of 1, 2 and 7 in the yeast.
(A) HPLC analysis (at 420 nm) of the products of S. cerevisiae BJ5464-NpgA harboring plasmids
to express different sets of genes: empty vectors (i), pSUN39+pSUN64+pSUN147 (ii),
pSUN39+pSUN143+pSUN147 (iii), pSUN39+pSUN143+pSUN164 (iv). (B) Analysis of the
production of 1, 2, and 7, using S. cerevisiae BJ5464-NpgA/ pSUN39+pSUN143+pSUN147 or
pSUN39+pSUN143+pSUN164 was cultured in YPD medium with 1% pyruvate, compared with
S. cerevisiae BJ5464-NpgA/pSUN39+pSUN143. For 7, samples were collected from 4-days’
culture, and for 1 and 2, samples were harvested after 7 days.

Previous research reported that introduction of the S1157A mutation into ACC1 prevents
deactivation of this enzyme during the shift in carbon source from glucose to ethanol [33]. To
provide more malonyl-CoA for polyketide synthesis, we introduced the site-directed mutant
ACC1S1157A in the biosynthetic pathway of 1, 2 and 7. A plasmid was constructed harboring
acc1S1157A under the Adh2 promoter (pSUN164) and co-expressed with plasmids containing emoA
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and acte1 in S. cerevisiae BJ5464-NpgA. The strains were cultivated under the same conditions
as described before, and samples were assayed for 1, 2 and 7 by HPLC (trace iv, Fig. 9A). All
strains still contain the endogenous acc1 gene under the ACC1 native promoter. As shown in Fig.
9B, compared to wild type ACC1, the strain with ACC1S1157A had produced 1, 2 and 7 with titers
increased by 111.7%, 47.7% and 48.2%, respectively. The final titers for products were 1: 669.3
± 41.5 mg L-1, 7: 412.1 ± 45.6 mg L-1, and 2: 369.4 ± 36.1 mg L-1 for the engineered strain with
EmoA, ACTE1 and ACC1S1157A co-expressed.

According to the previous findings, 2 has more pharmaceutical values than 1 and 7 [9-12].
Therefore, it is desirable to further increase the production of 2. To this end, we introduced an
enzyme which can serve as a decarboxylase on the process of transformation from 1 to 2. A
bifunctional enzyme HYP3 from Shiraia sp. strain Slf14 was found to have the activity of
decarboxylase. Thus, it was co-expressed with EmoA-ACTE1-ACC1S1157A in the yeast. Another
enzyme TpcK, which serves in the decarboxylation in the biosynthesis of 2 [34], was also coexpressed with EmoA-ACTE1-ACC1S1157A. As shown in Fig. 10 A, products 1, 2 and 7 were
synthesized. The engineered strain S.

cerevisiae BJ5464-NpgA/EmoA-ACTE1-ACC1S1157A-

HYP3 produced 2 in a titer 27.3% higher than the strain without HYP3, whereas the titer of 1 was
decreased by 22.9% (trace ii, iii, Fig. 10 A). Compared to S. cerevisiae BJ5464-NpgA/EmoAACTE1-ACC1S1157A, the engineered strain S.

cerevisiae BJ5464-NpgA/EmoA-ACTE1-

ACC1S1157A-TpcK produced 55.4% more of 2 and 53.1% less 1. In conclusion, TpcK and HYP3
both increased the production of 2 and reduced the accumulation of endocrocin by serving as a
decarboxylase in the biosynthesis of 2. The final titers for 2 was 592.5 ± 51.6 mg L-1 for the
engineered S. cerevisiae BJ5464-NpgA harboring EmoA-ACTE1-ACC1S1157A-TpcK (Fig. 10 B).
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Fig. 10 Improved production of 2 by engineering TpcK or HYP3 into the biosynthetic pathway.
(A) HPLC analysis (420 nm) of the production of compounds 1, 2 and 7 in engineered S. cerevisiae
BJ5464-NpgA strains, harboring empty vectors (i), pSUN39+pSUN143+pSUN164+pSUN108 (ii),
and pSUN39+pSUN143+pSUN164+pSUN207 (iii), respectively. For analysis of the production
of 7, samples were collected in 4-days’ culture; for 1 and 2, samples were harvested in 7-days’s
culture. (B) Quantitative analysis of the production of compounds 1, 2 and 7 using S. cerevisiae
BJ5464-NpgA/

pSUN39+pSUN143+pSUN164+pSUN108

pSUN39+pSUN143+pSUN164+pSUN207,

compared

to

the

same

or
host

harboring

pSUN39+pSUN143+pSUN164 cultured in the same medium.

2.3.4 Production of emodin in P. pastoris GS115
As shown in our results, we have reconstituted the biosynthetic pathway to efficiently produce
emodin in S. cerevisiae. Since the P. pastoris cell factory is approved by FDA for commercial
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application on a variety of recombinant biopharmaceutical products. In order to produce emodin
for industrial use, the engineered strain P. pastoris GS115-npgA-tpcK-emoA-acte1 was
constructed via transformation of plasmids pSUN201 (linearized with PmeI) and pSUN227
(linearized with SalI). The P. pastoris transformants are selected on histidine-deficient medium
MGY plus zeocin. In order to analyze the emodin production in P. pastoris, the blank control strain
P. pastoris GS115 and engineered strain P. pastoris GS115-npgA-tpcK-emoA-acte1 were
cultivated in flasks under the same conditions. After methanol induced expression for 72 hr, the
samples were extracted and analyzed by HPLC. As shown in Fig. 11, P. pastoris GS115-npgAtpcK-emoA-acte1 produced two specific compounds, which had the same retention times as an
authentic sample of endocrocin and emodin under this elution condition. The compounds were
confirmed by UV absorption spectrum and molecular weights.

Fig. 11 HPLC analysis (420 nm) of the products of P. pastoris GS115-npgA-tpcK-emoA-acte1 (ii),
P. pastoris GS115 as control (i).

A 5-L bioreactor fermentation was subsequently conducted to evaluate the productivity of 1
and 2 by the recombinant P. pastoris GS115-npgA-tpcK-emoA-acte1. A batch phase in MM
medium proceeded until 36 hr when the wet cell weight (WCW) reached 141.6 g L-1. The carbon
source glycerol was used up and dissolved oxygen sharply increased. An additional 36 mL of

43

glycerol was added to further improve cell growth until 48 hr when a high cell density of 233.8 g
L-1 (WCW) was achieved. After glycerol was completely consumed, methanol was added to 1%
v/v. The AOX1 promoter was thus activated, and 1 and 2 were rapidly synthesized and
accumulated. After induction for 72 hr, the titer of 1 reached 239.6 ± 33.7 mg L-1 and 2 was
produced at 534.8 ± 42.9 mg L-1. Approximately 79.6% and 81.3% of 1 and 2 were obtained from
the broth extracts, while 21.4% and 19.7% of 1 and 2 were from the cells extracts. Production of
7 was not observed.

2.3.5 The biosynthetic pathway of emodin and endocrocin
Endocrocin and emodin are assembled by a fungal type I PKS. As previously reported, the
bicyclic intermediate 9 is directly cyclized to 8 by spontaneous enol lactonization [43] (Fig. 12 A).
According to previous research, a putative hypocrellin A biosynthetic gene hyp1 was identified as
a type I PKS [39] and hyp3 is located near the hyp1 gene on the genome of Shiraia sp. Strain Slf14.
HYP3 is homologous to CTB3 from Cercospora nicotianae that was discovered to decarboxylate
8 [35]. HYP3 was thus proposed to have a similar function as CTB3 (Fig. 12A). Atrochrysone (7)
was one of the major products of in vivo expression of EmoA-EmoB or EmoA-ACTE1 in S.
cerevisiae BJ5464-NpgA. We proposed that the direct product of the NR-PKS was atrochrysone
carboxylic acid (10) (Fig. 12 B). However, 10 was not detected, likely due to the instability and its
tendency to readily convert to atrochrysone (7) or endocrocin anthrone (11). Since β-keto acids
have a low energy path for decarboxylation, they are generally decarboxylated [44]. When 10 has
the ketone group at the β-position relative to the carboxyl group, decarboxylation occurs readily,
yielding 7. If dehydration instead of decarboxylation of 10 occurs, 11 will be formed, which will
be spontaneously oxidized into 1. According to the time course results, with the titer of 7 decreased,
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1 and 2 were accumulated. Compound 2 could be derived from 7 instead of 1, because previous
research reported that the carboxyl group of 1 is stable, and acid treatment of 7 yielded emodin
anthrone and 2 [20]. However, when we added HYP3 or TpcK into the pathway, the accumulation
of 1 was significantly decreased. This result proved that TpcK or HYP3 serves as a decarboxylase
on 1. Since 1 is the native substrate of TpcK [34], TpcK has a higher efficiency than HYP3.

Fig. 12. Proposed biosynthetic pathway of 8 (A) as well as 1, 2 and 7 (B).

2.4 Conclusion
In this work, I identified a TE-less NR-PKS (EmoA) and the adjacent MβL-TE (EmoB) from
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Shiraia sp. strain Slf14, and identified another similar type I PKS gene cluster ACPKS and ACTE1
in A. candidus. From heterologous co-expression of EmoA-EmoB or EmoA-ACTE1 in S.
cerevisiae, we found that the ACTE1 has a higher efficiency than EmoB on releasing the
polyketide products. The direct substrate for emodin and endocrocin biosynthesis is malonyl-CoA.
In order to further improve the supply of malonyl-CoA in S. cerevisiae, a site-directed mutated
acetyl-CoA decarboxylase (acc1) was introduced into the biosynthetic pathway. The production
of endocrocin and emodin was significantly increased. I also optimized the fermentation conditions
by adding extra carbon sources to supply more substrate for polyketide biosynthesis. The results
showed that pyruvate is the most efficient carbon source for emodin and endocrocin production.
For further increasing the production of emodin, endocrocin decarboxylase HYP3 or TpcK was
introduced into the pathway. The accumulation of endocrocin was decreased, whereas the emodin
production was significantly increased. TpcK exhibited a higher decarboxylation efficiency than
HYP3. In this research, we also engineered P. pastoris GS115 by introducing the npgA-emoAacte1-tpcK gene cluster and constructed an efficient cell factory for emodin production, which
provides an efficient producing strain for industrial production of emodin.
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CHAPTER III MANIPULATION OF TWO REGULATORY GENES FOR EFFICIENT
PRODUCTION OF CHROMOMYCINS IN STREPTOMYCES RESEISCLEROTICUS

ABSTRACT
The glycosylated polyketide compounds chromomycins belong to a family of aureolic acid
natural products, many of which have shown strong anti-tumor bioactivities. A silent type II
polyketide biosynthetic gene cluster was discovered in S. reseiscleroticus, which consists of thirty
six open reading frames and is silent under lab conditions. Heterologous expression of the minimal
PKS (srcmKPS) in Streptomyces lividans K4-114 produced a decaketide, indicating that this gene
cluster is involved in the biosynthesis of chromomycins. In the gene cluster, two regulatory genes
were found, including SARP-type activator SrcmRI and PadR-like repressor SrcmRII. When
SrcmRI was overexpressed in S. reseiscleroticus, the silent biosynthetic gene cluster of
chromomycins was activated. The production titers of chromomycins A2 and A3 reached 11.3 and
13.4 mg L-1, respectively. Disruption of the inhibitor SrcmRII gene has a more significant effect
on chromomycins production, and the titers of chromomycins A2 and A3 reached 64.4 and 55.8
mg L-1. An engineered strain was then constructed with both SrcmRII disruption and SrcmRI
overexpression, which produced chromomycins A2 and A3 at 85.4 and 71.3 mg L-1, respectively.
Optimization of the culture conditions further improved the titers of chromomycins A2 and A3
respectively to 158.3 and 145.1 mg L -1. Therefore, from the native non-producing strain of S.
reseiscleroticus, an efficient producing engineered strain of chromomycins has been created,
which may facilitate the production of these pharmaceutically valuable molecules in the industry.
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3.1 Introduction
Chromomycins are glycosylated polyketide compounds that were first found in Streptomyces
griseus. They belong to a group of canccrostatic and antitumor antibiotics [1]. Chromomycins and
mithramycins, representative compounds of the aureolic acid family, are effective against various
human tumors such as brain and testicular carcinomas [2, 3]. Recently, chromomycin A3 was also
reported to enable the stimulation of K562 cell erythroid differentiation [4]. It was used in the
neurological therapeutics [5] and showed activities against HIV-1 [6]. Chromomycin A3 has been
clinically used as an anticancer drug since 1960s [7], and chromomycins A2, which has similar
bioactivities, is the major byproduct isolated during the manufacture of chromomycin A3.

S. roseiscleroticus (ATCC® 53903) was known to produce an antitumor drug sultriecin [8].
The genome of this strain has been recently sequenced by our group. One putative type II PKS
gene cluster was discovered in this strain, which could be involved in the biosynthesis of
chromomycins based on bioinformatics analysis. We also found several regulatory genes in the
gene cluster, including the activator (srcmRII) and repressor (srcmRI) genes, which may play roles
in the regulation of the whole gene cluster. Activation of antibiotic biosynthesis is genetically
controlled at several levels. The most fundamental level involves genes encoding pleiotropic
regulators which control both secondary metabolism and morphological differentiation. At the
next level, genes exert their control over two or more antibiotics in the same organism but have no
effects on morphological differentiation. Finally, the most specific level of control concerns genes
encoding regulators that act only on one biosynthetic pathway [9]. These genes, whose expression
is partly dependent on pleiotropic regulators, are usually found physically linked to the structural
antibiotic biosynthetic genes on the chromosomes of streptomycetes. This is different from the
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global regulatory genes which can be located far from the clusters they control. In most cases, the
pathway-specific regulators play a positive role in the transcription of the biosynthetic genes, while
others may act as transcriptional repressors. The group of proteins referred to as
streptomyces antibiotic regulatory proteins (SARPs) is prominent among the pathway-specific
regulators in streptomycetes [9].

In gram-positive bacteria, the phenolic acid decarboxylase (Pad) gene is involved in the
phenolic acid stress response. Phenolic acids are decarboxylated by inducible Pad enzymes into
vinyl phenol derivatives, which are not toxic to gram-positive bacteria. The phenolic acid
decarboxylase repressor (PadR) gene encodes the transcriptional regulator that represses genes
associated with the phenolic acid stress response in gram-positive bacteria such as Bacillus subtilis,
Pediococcus pentosaceus, and Lactobacillus plantarum [10-12]. Among these transcriptional
regulators, only a few of the PadR-like proteins have been investigated, such as AphA, which
activates virulence gene expression in Vibrio cholera [13], LmrR and LadR, which inhibit the
expression of a multi-drug resistance pump in Lactococcus lactis and Listeria monocytogenesis,
respectively

[14,

15],

and

CmmRII,

a

transcriptional

repressor

of

chromomycin

resistance/biosynthesis in S. griseus subsp [16].

3.2 Materials and Methods

3.2.1 General method
Products were analyzed and purified on an Agilent 1200 HPLC instrument. ESI-MS spectra
were obtained on an Agilent 6130 quadrupole LC-MS. NMR spectra were recorded on a JEOL
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NMR instrument (300 MHz for 1H NMR, 75 MHz for 13C NMR). The chemical shift (δ) values
are given in parts per million (ppm). The coupling constants (J values) are reported in Hertz (Hz).

3.2.2 Microorganisms, culture conditions, and plasmids
E. coli DH5α and ET12567 were grown in Luria-Bertani broth. S. roseiscleroticus (ATCC®
53903) and S. lividans K4-114 was cultured in ISP4 medium for seed culture preparation. R5A
and YEME medium were used as the fermentation medium for chromomycins production, and
TSBY salt medium was for double crossover [8, 11]. For conjugation, the streptomyces strains
were grown in TSB medium. R5A medium was used for genomic DNA isolation [11]. The plasmid
pRM5 was used for heterologous gene expression in S. lividans K4-114. For gene manipulations
in S. roseiscleroticus, plasmid pSET152 was used for gene overexpression, and pKC1139 for gene
disruption (Table 5). The concentrations of antibiotics used were 50 μg mL-1 for ampicillin, 50 μg
mL-1 for apramycin (Am), 50 μg mL-1 for thiostrepton, and 50 μg mL-1 for nalidixic acid (NC).

55

Table 5. List of strains and plasmids used in Chapter III.
Strains

Genotype

Source

S. roseiscleroticus
S. lividans K4-114
SR1
SR2
SR3
KS1

WT
pro-2 str-6SLP2 − SLP3 −act::ermE Streptomyces
S. roseiscleroticus/ pSET152-srcmRI
S. roseiscleroticus/ ∆srcmRII::aac (3) IV
S. roseiscleroticus/ ∆srcmRII::aac (3) IV , pSET152-srcmRI
S. lividans K4-114/ pRM5-srcmKPS

ATCC
Lab Stock
This Work
This Work
This Work
This Work

Plasmids
pZJ172
pZJ178
pZJ179
pSUN6
pTZ3
pZJ183
pZJ191
pZJ192
pZJ194
pZJ195
pZJ196

Description
srcmS in pJET1.2
srcmKPS in pJET1.2
srcmRI in pJET1.2
srcmKPS in pRM5
oxyABC in pRM5
srcmRI in pSET152
srcmRII knockout left arm in pJET1.2
srcmRII knockout right arm in pJET1.2
srcmRII knockout left arm in pKC1139
srcmRII knockout right arm in pKC1139
srcmRII knockout right arm-left arm in pKC1139

Source
This Work
This Work
This Work
This Work
This Work
This Work
This Work
This Work
This Work
This Work
This Work

3.2.3 DNA manipulation and sequence analysis
General DNA manipulations were performed as described previously [1]. PCRs were
performed using the Phusion DNA polymerase kit (Thermo Scientific, USA). S. roseiscleroticus
and Streptomyces rimosus genomes were isolated by a standard procedure [17]. Conjugation
transformation was performed as described previously [18]. Homologous sequence database
searching and multiple alignments were executed with BLASTP and ClustalX. The gene cluster
was annotated with FramePlot [19].

3.2.4 Heterologous expression of minimal PKS in S. lividans K4-114
The minimal PKS genes srcmKPS were cloned from S. roseiscleroticus genome. srcmKP
genes were amplified using PCR with the primers KS-F-PacI and CLF-R-EcoRI-NheI (Table 6)
and ligated into pRM5 at PacI/NheI sites. We amplified the srcmS gene with primers ACP-F-SpeI
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and ACP-R-NheI (Table 6) and ligated it into pRM5-srcmKP at the NheI site to yield pSUN6, PacI
and NheI was used to determine the correct direction. Introduction of pSUN6 into the host strain
S. lividans K4-114 via protoplast transformation afforded strain KS1 (Table 5). Using genomic
DNA of S. rimosus as template, the oxyAB genes were amplified with primers OxyA-5-PacI and
OxyB-3-NheI and ligated into pRM5 at PacI/NheI sites. The oxyC gene was amplified using PCR
with primers OxyC-5-SpeI and OxyC-3-NheI (Table 6) and ligated into pRM5-oxyAB at the NheI
site to yield pTZ3. PacI and NheI was used to determine the correct direction.

Table 6. List of primers used in Chapter III. *
Primers
KS-F-PacI
CLF-R-EcoRI-NheI
OxyA-5-PacI
OxyB-3-NheI
OxyC-5-SpeI
OxyC-3-NheI
ACP-F-SpeI
ACP-R-NheI
14-2-SARP-F-XbaI-NdeI
14-2-SARP-R-XbaI
PadRout-left-F-EcoRI
PadRout-left-R-XbaI
PadRout-right-F-XbaI
PadRout-right-R-HindIII
PadRout-confirm-F
PadRout-confirm-R

Sequence
5'-AATTAATTAAGGAGGAGCCCATATGAGAAGGCGCGTCGTGGT-3'
5'-AAGAATTCGCTAGCCTACGGTCCCGACAGCGCCA-3'
5'-AATTAATTAAGGAGGAGCCCATATGTCCAAGATCCATGACGC-3'
5'-AAGCTAGCTCAGTCCCGGCCGCTGACCA-3'
5'-AAACTAGTGGAGGAGCCCATATGACCCTGCTCACCCTCTC-3'
5'-AAGCTAGCTCACTTGTCCCGCGCGGCGC-3'
5'-AAACTAGTGGAGGAGCCCATATGATGACGGTGGACGATCT-3'
5'- AAGCTAGCTCAGCCCACCCCGATGCCGT-3'
5'- AATCTAGAGGAGGAGCCCATATGAGCTCCGACAGCGACTGCA-3'
5'- AATCTAGATCAGCCGGCCCGGCGCTGCC-3'
5'- AAA GAATTC TACTCGCCGGAGTGCGCACGGTCGAA-3'
5'- AAA TCTAGA CTTCTTCGCGCAGCTTGCGCAGCT-3'
5'- AAA TCTAGA CGTACCGCTGTCGCCGCGAT-3'
5'- AAA AAGCTT ATGATCTCGATCATCGAGCG-3'
5'-AACATATGGCTCTGGGCACGCTGCA-3'
5'-AAGAATTCTCACTGCGGGTCCTCCTGCG-3'

* The restriction sites are underlined.

3.2.5 Overexpression of SARP in S. roseiscleroticus
This SARP gene srcmRI was PCR amplified with primers 14-2-SARP-F-XbaI-NdeI and 14-2SARP-R-XbaI (Table 6) and ligated into pSET152 at the XbaI site under the ermE promoter to
yield pZJ183, the NdeI site was designed to determine the correct direction. Introduction of pZJ183
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into wild type S. roseiscleroticus by protoplast transformation afforded the recombinant strain SR1
(Table 5), in which the expression of srcmRI is under the control of the constitutive ermE promoter
[17].

3.2.6 Gene disruption of PadR in S. roseiscleroticus
The srcmRII gene was inactivated by gene replacement to construct ∆srcmRII mutant. The
homologous arms were amplified with two sets of primers. PadRout-left-F-EcoRI and PadRoutleft-R-XbaI (Table 6) were used to amplify the left arm, which was ligated into pKC1139 at
EcoRI/XbaI sites to yield pZJ194. PadRout-right-F-XbaI and PadRout-right-R-HindIII (Table 6)
were used to amplify the right arm, which was cloned into pKC1139 at XbaI/HindIII sites to yield
pZJ195. The left homolog arm was subsequently ligated into pZJ195 at the EcoRI/XbaI sites,
yielding pZJ196 (Table 5). After introduction of pZJ196 into the wild type S. roseiscleroticus
strain via E. coli-S. roseiscleroticus conjugation, transformants were cultured at 37 C to screen
for a apramycin-resistant phenotype to identify single-crossover mutants. The single-crossover
mutants were cultured on blank TSBY salt plates for several generations, and then transferred onto
the TSBY salt plates with or without apramycin. After 7 days’ culture, I screened the TSBY plates
for the double-crossover colonies which lost the apramycin-resistant phenotype. The strains that
grew on blank TSBY salt plates but did not grow with apramycin was selected as double-crossover
candidates. The double-crossover candidates were further confirmed by PCR with primers
PadRout-confirm-F and PadRout-confirm-R (Table 6). The PCR product was also sequenced for
further confirmation. After the double-crossover strain was confirmed, it was named as SR2.
pZJ183 was transferred into the SR2 strain via conjugation to yield SR3 which has both srcmRII
deletion and srcmRI overexpression.
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3.2.7 Detection and purification of chromomycins A3 (3), A2 (4) and SEK15b (12)
S. roseiscleroticus or S. lividans K4-114 grown on solid media were extracted with the method
described before [1]. The liquid culture broth of S. roseiscleroticus or S. lividans K4-114 was first
centrifuged at 3,000 ×g to harvest the cells. The supernatant of the broth was extracted three times
with an equal volume of ethyl acetate, and the pellet cells were extracted with methanol. The two
part extracts were combined and dried with rotavapor. The residue was dissolved in 10 mL of
methanol. To establish the standard curves, chromomycins were analyzed and purified on an
Agilent 1200 HPLC instrument. NMR spectra were collected in CDCl3 for 3 and 4, and in DMSOd6 for 12. The crude extract was fractionated using a silica gel-60 column, eluted with different
ratios of methanol-chloroform (0:100, 1:99, 2:98, 3:97, 5:95, 10:90, 15:85, v/v, each 250 mL) to
afford seven fractions. The fractions containing the target compounds were further separated by
HPLC (Agilent Eclipse Plus C18, 5 μm, 4.6 mm × 250 mm), eluted with acetonitrile-water at a
flow rate of 1 mL min−1. 4, found in fraction 2, was further purified using HPLC with an isocratic
elution of 47% acetonitrile in water. The target peak at 15.4 min was collected to yield 22.3 mg of
4 in a pure form. 3 was found in fraction 3 and was purified by HPLC with an isocratic elution of
43% acetonitrile/water. The target peak at 13.6 min was collected to yield 10.5 mg of 3 in a pure
form.
The pure compounds were dissolved in 1 mL of methanol:DMSO (50:50), which was serially
diluted to obtain different concentrations. For each concentration, 100 μL of these samples were
injected into the HPLC to obtain the peak areas to establish standard curves for 3 and 4. Standard
curves based on the linear relationship between the amounts (µg) and the peak areas (420 nm)
were established for 3 (y = 114.38x - 853.13, R² = 0.9965) and 4 (y = 44.436x + 196.1, R² = 0.9912)
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for quantification of their production in different engineered strains. 12 was extracted from liquid
culture broth of strain KS1, using the same method. The crude extract was also fractionated on a
silica gel-60 column using the same strategy as described above. 12 was observed in fraction 4. It
was purified using HPLC by an isocratic elution with 37% acetonitrile in water. The target peak
at 17.1 min was collected to yield 9.1 mg of 12 in a pure form.

3.2.8 Fermentation and products analysis
For the time-course analysis, 106 mL-1 spores of S. roseiscleroticus wild type or the engineered
strain SR3 were inoculated respectively into 500 mL of liquid YEME in 2-L flask at 28 C. The
fermentation broths were sampled (10 mL) at 0, 1, 2, 3, 4 and 5 days and the products were
analyzed on an Agilent 1200 HPLC instrument (Agilent eclipse plus C18, 5 μm, 4.6 mm × 250
mm) using a linear gradient of 10% to 90% acetonitrile-water (containing 0.1% trifluoroacetic acid)
over 45 min at a flow rate of 1 mL min-1. For production analysis in solid medium, 106 mL-1 spores
of wild type S. roseiscleroticus, engineered strains SR1, SR2 and SR3 were inoculated respectively
onto R5A or YEME solid medium, and incubated at 28 C for 7 days. The extraction and analysis
methods were described as above.

3.3 Results

3.3.1 Analysis of the chromomycins biosynthesis gene cluster
The genomic DNA of Streptomyces reseiscleroticus was sequenced by our group. Annotation
of the genes revealed a type II polyketide biosynthetic gene cluster that consists of thirty six genes
and might be involved in the biosynthesis of 3 and 4. Mithramycin shares the same aglycon
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structure with chromomycins, and the biosynthetic pathway of mithramycin has been well studied
[20]. The putative chromomycin biosynthetic gene cluster in S. reseiscleroticus is similar to that
for mithramycin and chromomycin A3 in S. griseus (Fig. 13) [1]. Three enzymes SrcmP, K and S
are the minimal PKS which might be responsible for the biosynthesis of the decaketide backbone
of the chromomycin aglycon. SrcmQ, X and Y would be involved in cyclization and aromatization
process. SrcmOI, OII and OIV are predicted to be oxygenases involved in the hydroxylations of
aromatic polyketides. Since the chromomycin aglycon contains two methyl groups, SrcmMII and
MIII are proposed to be involved in this methylation process. There are several enzymes predicted
to be involved in glycosylation and modification on the deoxysugars side chains, including SrcmD,
E, F, V, WI, MI, the glycosyltransferases SrcmGI-IV and NDP-4-ketoreductases SrcmUI-III.
SrcmH, I, J might be involved in self-resistance. SrcmRI and RII are putative regulatory proteins,
likely involved in the regulation of the biosynthetic pathway of chromomycins (Table 7).

Fig. 13 Genetic organization of the srcm gene cluster.
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Table 7. Putative functions of the genes of the chromomycin biosynthetic gene cluster.
Gene

Annotation

Size (aa)

Homologue

Identity

srcmA

acetyltransferase

318

acetyltransferase [Streptomyces griseus subsp. griseus]

74%

srcmC

NDP-C-methyltransferase

409

NDP-C-methyltransferase [Streptomyces griseus subsp. griseus]

78%

srcmD

NDP-glucose synthase

355

NDP-glucose synthase [Streptomyces griseus subsp. griseus]

70%

srcmE

NDP-4,6-(glucose)-dehydratase

322

NDP-4,6-dehydratase [Streptomyces griseus subsp. griseus]

75%

srcmF

NDP-5-epimerase

194

NDP-5-epimerase [Streptomyces griseus subsp. griseus]

77%

srcmGI

glycosyltransferase

394

ChlC7 [Streptomyces antibioticus]

42%

srcmGII

glycosyltransferase

400

glycosyltransferase [Streptomyces griseus subsp. griseus]

72%

srcmGIII

glycosyltransferase

391

PyrC4 [Streptomyces rugosporus]

41%
43%

srcmGIV

glycosyltransferase

259

UDP:flavonoid glycosyltransferase YjiC, YdhE family [Streptomyces sp.
Ag82_G6-1]

srcmH

ABC transporter membrane protein

251

membrane protein [Streptomyces griseus subsp. griseus]

84%

srcmI

ABC transporter ATP-binding protein

322

ATP-binding protein [Streptomyces griseus subsp. griseus]

77%

srcmJ

Excinuclease ABC subunit A

1650

UV-repair protein [Streptomyces griseus subsp. griseus]

79%

srcmK

ketosynthase

422

ketosynthase [Streptomyces griseus subsp. griseus]

84%

srcmLI

acyl CoA ligase

409

acyl CoA ligase [Streptomyces griseus subsp. griseus]

68%

srcmLII

acyl CoA ligase

536

acyl CoA ligase [Streptomyces rimosus]

53%

srcmMI

sugar O-methyltransferase

252

AlmCII [Streptomyces sp. A1]
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srcmMII

C-methyltransferase

343

C-methyltransferase [Streptomyces griseus subsp. griseus]

74%

srcmMIII

O-methyltransferase

329

CtcO [Kitasatospora aureofaciens]

51%

srcmOI

oxygenase

423

oxygenase [Streptomyces griseus subsp. griseus]

70%

srcmOII

oxygenase

550

DacO2 [Dactylosporangium sp. SC14051]

57%

srcmOIV

FAD-dependent monooxygenase

511

DacO3 [Dactylosporangium sp. SC14051]

49%

srcmP

polyketide chain length factor

402

ketosynthase [Streptomyces griseus subsp. griseus]

76%

srcmQ

aromatase

320

aromatase [Streptomyces griseus subsp. griseus]

71%

srcmRI

transcriptional regulator

292

transcriptional regulator [Streptomyces griseus subsp. griseus]

71%

srcmRII

transcriptional regulator

186

transcriptional regulator [Streptomyces griseus subsp. griseus]

77%

srcmS

acyl carrier protein

82

acyl carrier protein [Streptomyces griseus subsp. griseus]

65%

srcmTI

ketoreductase

105

ketoreductase [Streptomyces griseus subsp. griseus]

73%

srcmTII

ketoreductase

253

ketoreductase [Streptomyces griseus subsp. griseus]

74%

srcmUI

NDP-4-ketoreductase

252

NDP-hexose 4-ketoreductase UrdR [Streptomyces fradiae]

51%

srcmUII

NDP-4-ketoreductase

192

SaqR [Micromonospora sp. Tu 6368]

52%

srcmUIII

NDP-4-ketoreductase

335

PyrC3 [Streptomyces rugosporus]

48%

srcmV

NDP-2,3-dehydratase

517

Sim20 [Streptomyces antibioticus]

48%

srcmW

NDP-3-ketoreductase

331

PokS4 [Streptomyces diastatochromogenes]

53%

srcmWI

side-chain ketoreductase

326

side-chain ketoreductase [Streptomyces griseus subsp. griseus]

76%

srcmX

cyclase

258

cyclase [Streptomyces griseus subsp. griseus]

76%

srcmY

cyclase

142

cyclase [Streptomyces griseus subsp. griseus]

71%

The minimal PKS consisting of SrcmK (ketosynthase), SrcmP (polyketide chain length factor)
and SrcmS (acyl carrier protein) are proposed to synthesize a decaketide backbone. The decaketide
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backbone will be cyclized with the participation of the aromatase SrcmQ to form the first ring,
which will be further folded and modified by the cyclases (SrcmX and SrcmY) and ketoreductases
(SrcmTI and SrcmTII) to form a four-ring structure. Two hydroxyl groups will be introduced by
the oxygenases Srcm OI and SrcmOII to form 4-demethyl-premithramycinone. The methylation
on 1'-hydroxy group is proposed to be catalyzed by SrcmMIII, a putative O-methyltransferase,
leading to the synthesis of premithramycinone. After the synthesis of aglycon part, several steps
of glycosylation will occur. Four glycosyltransferases SrcmGI-IV are proposed to transfer five
deoxysugars to premithramycinone. The deoxysugar biosynthesis starts from the activation of
glucose-1-phosphate to NDP-D-glucose catalyzed by a NDP-glucose synthase SrcmD, which is
then converted to NDP-4-keto-6-deoxy-glucose by SrcmE (NDP-glucose 4,6-dehydratase). The
intermediate is deoxygenated at C-2 into NDP-4-keto-2,6-dideoxy-D-glucose through 2,3dehydration and a C-3 reduction catalyzed by SrcmV and SrcmW, respectively. The NDP-4ketoreductases SrcmUI and SrcmUII are involved in the conversion of NDP-4-keto-2,6-dideoxyD-glucose into NDP-D-olivose or NDP-D-oliose. SrcmUIII (NDP-4-ketoreductase), SrcmC
(NDP-C-methyltransferase) and SrcmF (NDP-5-epimerase) are probably involved in the synthesis
of L-olivomycose. The acetylations of sugars A and E are likely catalyzed by the SrcmA
(acyltransferase). After two units of D-olivose and one unit of 4-O-acetyl-L-olivomycose are
subsequently attached to the aglycon at 2-OH, the C-methylation at the C-7 position is catalyzed
by SrcmMII (C-methyltransferase). For the biosynthesis of chromomycin A2, SrcmMII would
probably catalyze the methylation on the acetyl group of the 4-O-acetyl-L-olivomycose to form a
4-O-methylpropionyl-L-olivomycose. The O-methylation on D-oliose catalyzed by SrcmMI
(sugar O-methyltransferase) will yield 4-O-methyl-D-olivose. Similar to MtmOIV [20], SrcmOIV
is a putative FAD-dependent monooxygenase and would probably be responsible for opening the
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fourth ring and generate the tricyclic aglycon with the pentyl side chain attached at the C-3 position,
which form the ultimate structure of chromomycin A2 or A3 (Fig. 14). In summary, the type II
polyketide biosynthetic gene cluster we found in S. reseiscleroticus is consistent with the proposed
biosynthetic pathway of chromomycins A2 and A3.

Fig. 14 Proposed biosynthetic pathway of chromomycins A2 and A3.

3.3.2 Heterologous expression of type II minimal PKSs in S. lividans K4-114
According to the annotation of the gene cluster in S. roseiscleroticus, srcmKPS are putative
minimal PKS genes in the chromomycins biosynthesis. In order to confirm the function of
SrcmKPS, we constructed a plasmid pRM5-srcmKPS (pSUN6) and introduced it into S. lividans
K4-114 for heterologous expression. As shown in trace i of Fig. 15 A, a major product 12 at 21.6
min was observed in the extract of engineered strain KS1. In order to identify compound 12, a
scaled up broth was prepared. ESI-MS analysis of 12 showed ion peaks [M+H]+ at m/z 381 and
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[M+H]- m/z 379, indicating that the molecular weight of this compound is 380, which corresponds
to that of SEK15b. The 1H NMR (Table 8) of 12 indicated that the compound has five aromatic
proton signals and one high field methyl group signal. Twenty carbons were observed in the 13C
NMR spectrum (Table 8) of 12. After the comparison with published data [21], compound 12 was
identified as SEK15b. Therefore, SrcmKPS were confirmed to be the minimal PKS for the
biosynthesis of decaketide. For the reference, we constructed another pRM5-based expression
plasmid (pTZ3) carries the OxyABC genes which is the minimal PKS for the biosynthesis of
oxytetracycline. As shown in trace ii of Fig. 15 A, a peak was eluted at the same time as 12,
whereas S. lividans K4-114 harboring empty vector pRM5 did not produce 12 (trace iii, Fig. 15
A). The oxytetracycline minimal PKS OxyABC was previously reported to synthesize a decaketide
which will be spontaneously cyclized into SEK15b (Fig. 15 B) [22]. Therefore, we further
confirmed that SrcmKPS has the same function as OxyABC.

Fig. 15 Heterologous expression of SrcmKPS in S. lividans K4-114. (A) HPLC analysis of the
extracts of S. lividans K4 harboring expression plasmid pSUN6 (i), pTZ3 (ii) and empty pRM5
vector (iii) respectively. Compounds were detected at 420 nm. (B) Formation of SEK15b (12) by
spontaneous cyclization of the nascent decaketide chain.
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Table 8. 1H-NMR (300 MHz) and 13C-NMR (75 MHz) data for SEK15b (12) (DMSO-d6, δ in ppm,
J in Hz).
Position
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

13C

1H

164.5
89.7
170.1
105.5
157.8
127.4
136.9
181.9
134.1
107.2
164.5
108.4
164.2
110.3
187.9
122.5
160.2
112.2
143.8
20.0

11.98 (1OH, s)
5.46 (1H, s)
6.23 (1H, s)

7.07 (1H, s)
11.55 (1OH, s)
6.63 (1H, s)
13.22 (1OH, s)

11.11 (1OH, s)
7.67 (1H, s)
2.69 (3H, s)

3.3.3 Disruption of srcmRII in S. roseiscleroticus and products characterization
After we confirmed that the decaketide was synthesized by SrcmKPS, we sought to search for
chromomycins in the extract of wild type S. roseiscleroticus. However, there were no target peaks
observed (trace i, Fig. 16). Thus, this gene cluster was considered silent in S. roseiscleroticus under
the lab conditions. Regulatory genes play important roles in controlling the expression of antibiotic
biosynthetic pathways. srcmRII is one of the regulatory genes in the chromomycin biosynthetic
gene cluster. BLAST analysis indicated that this gene encodes a PadR-like family transcriptional
regulator (PadR) and is a putative repressor. To identify the role of srcmRII in the biosynthesis of
3 and 4, we attempted to inactivate srcmRII in S. roseiscleroticus. To this end, we constructed
pZJ196 that is a derivative of pKC1139 harboring the homolog arms flanking srcmRII. After the
transformation of S. roseiscleroticus with this plasmid and subsequent homologous recombination,
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an engineered strain SR2 was obtained. This engineered strain was cultured onto R5A solid
medium, with wild type S. roseiscleroticus as control. HPLC and ESI-MS analysis revealed that
the wild type strain did not produce chromomycins on R5A medium, while the engineered strain
SR2 produced two new main products (traces i and ii, Fig. 16).

Fig. 16 Activation of the silent srcm biosynthetic pathway by disrupting srcmRII in S.
roseiscleroticus. Wild type and engineered strains were cultured on the R5A medium: wild type
(i), srcmRII (ii).

The two main products were purified and obtained as yellow pigments. They were identified
as chromomycins A2 (4) and A3 (3) based on spectroscopic analyses. Their molecular weights
were determined to be 1210 ([M-H]- m/z 1209.3, [M+Na]+ m/z 1233.4) and 1182 ([M-H]- m/z
1181.3, [M+Na]+ m/z 1205.4), respectively, based on the ESI-MS spectra. Their UV absorptions
were same as the previously reported [4]. The structures were further confirmed by comparing the
1H

NMR data with those in the literature [22-24]. In order to calculate the production of 3 and 4,

we established a standard curve for the relationship between the amounts of each pure compound
(µg) and the peak areas (420 nm). Based on the standard curve, the titers of 3 and 4 in strain SR2
were determined to be 49.3 ± 4.3 and 53.3 ± 3.6 mg L-1, respectively.

3.3.4 Overexpression of SrcmRI in S. roseiscleroticus
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Besides srcmRII, the other regulatory gene srcmRI is a Streptomyces antibiotic regulatory
protein (SARP), which was predicted to be the activator. To find out the role of srcmRI in the
biosynthesis of chromomycins, we attempted to overexpress the srcmRI gene in S. roseiscleroticus.
To this end, we constructed a pSET152-derived plasmid pZJ183 that harbors srcmRI under the
strong promoter ermP. After the transformation of S. roseiscleroticus with pZJ183, we obtained
the engineered strain SR1. The culture of this strain on R5A solid media was extracted and
analyzed as described before. As shown in trace ii, Fig. 15, compared to the wild type control
(trace i, Fig. 17), strain SR1 in R5A also produced 3 and 4. The average titers of 3 and 4 were 8.9
± 1.2 mg L-1 and 13.2 ± 1.6 mg L-1, respectively.

Fig. 17 Activation of the silent srcm biosynthetic pathway by srcmRI overexpression in S.
roseiscleroticus. Wild type and engineered strains were cultured on R5A agar: wild type (i),
srcmRI overexpression (ii).

3.3.5 Optimization of the production of chromomycins A2 (4) and A3 (3) in engineered S.
roseiscleroticus
According to our results, either inactivation of srcmRII or overexpression of the srcmRI gene
in S. roseiscleroticus increased the titers of 3 and 4. In order to further improve the production of
3 and 4, we tried overexpressing srcmRI in strain SR2, in which srcmRII was disrupted. The
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double-crossover strain SR2 was used as host and transformed with pZJ183 to get strain SR3,
which has both disrupted srcmRII and overexpressed srcmRI.

We cultured the engineered strain SR3 on R5A solid medium supplemented with apramycin,
as described above, and the culture was extracted and analyzed. As shown in trace ii, Fig. 18 A,
strain SR3 also produced 3 and 4. The titers of 3 and 4 were 69.4 ± 7.6 mg L-1 and 81.7 ± 7.2 mg
L-1, respectively. Compared to SR2 strain under the same culture conditions, the SR3 strain
produced approximately 48% more chromomycins (3 and 4). Strain SR3 produced approximately
7.5 folds more than SR1 did.

Since malonyl-CoA is the substrate for the aglycon, more sugar in the medium might provide
more carbon substrate for chromomycins biosynthesis. Additionally, sugar moieties are also
present in the side chains of chromomycins. In order to provide more sugar in the medium, we
attempted to use the yeast extract-malt extract (YEME) medium (1% glucose, 17% sucrose) for
chromomycins production. Three engineered strains SR1, SR2 and SR3 were cultured on YEME
solid medium for 7 days. As shown in Fig. 18 B, the production of 3 and 4 was significantly
increased in the YEME culture. Compared to the cultures on R5A medium, the production (3 plus
4) in YEME was much higher, with a 58.3% increase for SR1, 98.9% for SR2, and 95.8% for SR3.
The titers of 3 and 4 were 138.5 ± 15.6 mg L-1 and 157.3 ± 13.8 mg L-1, respectively.

These results further confirmed that SR3, with srcmRI overexpression and srcmRII disruption,
has higher production of chromomycins than the other two strains. Considering the further
application of this engineered strains in industry, we cultured SR3 in YEME liquid medium for
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time course analysis. The HPLC results (Fig. 18 C) showed that the titer has been increasing in the
first 3 days, and then reached a stable level. The highest titer of 3 was 145.1 ± 15.3 mg L-1, and
that of 4 was 158.3 ± 15.4 mg L-1. This engineered strain provides a great starting strain for efficient
production of these two products in pharmaceutical industry.

Fig. 18 Production of 3 and 4 by the engineered S. roseiscleroticus strains. (A) Wild type and
engineered strains were cultured in the R5A medium: wild type (i), strain SR3 (with srcmRI
overexpression and srcmRII disruption) (ii). (B) Production of 3 and 4 in different solid media. (C)
Time course analysis of production of 3 and 4 in liquid YEME.

3.4 Conclusion
In this chapter, we sequenced the genome of S. reseiscleroticus and discovered a type II
polyketide biosynthetic gene cluster consisting of thirty six open reading frames, which was
predicted to be involved in chromomycin biosynthesis. Heterologous expression of the minimal
PKS encoded by srcmKPS in S. lividans K4-114 confirmed that these enzymes synthesize the
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decaketide backbone of chromomycins. In the srcm gene cluster two putative regulatory genes
were identified, srcmRI encodes SARP-type activator, and srcmRII encodes a PadR-like repressor.
Overexpression of SrcmRI activated the biosynthetic pathway and biosynthesized chromomycins
A2 and A3, whereas the disruption of SrcmRII increased the production much more than SrcmRI
overexpression. In order to optimize the production of chromomycins, another engineered strain
SR3 was constructed by both overexpressing SrcmRI and disrupting SrcmRII. Under the optimized
culture conditions, chromomycin A2 was produced at 158.3 ± 15.4 mg L-1 and A3 at 145.1 ± 15.3
mg L-1. In conclusion, the inactivation of PadR-like repressor SrcmRII and overexpression of the
SARP-type activator SrcmRI transformed S. roseiscleroticus from a non-producing strain into an
efficient producer of chromomycins A2 and A3. The engineered strain showed the promise of
application in pharmaceutical industry.
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CHAPTER IV IDENTIFICATION OF A TYPE III POLYKETIDE SYNTHASE INVOLVED
IN THE BIOSYNTHESIS OF SPIROLAXINE*

ABSTRACT
Spirolaxine is a natural product isolated from Sporotrichum laxum ATCC® 15155, which has
shown a variety of biological activities including promising anti-Helicobacter pylori property. To
understand how this compound is biosynthesized, the genome of S. laxum was sequenced. Analysis
of the genome sequence revealed two putative type III polyketide synthase (PKS) genes in this
strain, Sl-pks1 and Sl-pks2, which are located adjacent to each other (~2.0 kb apart) in a tail-to-tail
arrangement. Disruption of these two genes revealed that Sl-PKS2 is the dedicated PKS involved
in the biosynthesis of spirolaxine. The intron-free Sl-pks2 gene was amplified from the cDNA of
S. laxum, and ligated into the expression vector pET28a for expression in Escherichia coli BL21CodonPlus (DE3)-RIL. The major products of Sl-PKS2 in E. coli were characterized as
alkylresorcinols that contains a C13-C17 saturated or unsaturated hydrocarbon side chain based on
the spectral data. This enzyme was purified and reacted with malonyl-CoA and a series of fatty
acyl-SNACs (C6-C10). Corresponding alkylresorcinols were formed from the decarboxylation of
the synthesized tetraketide resorcylic acids, together with fatty acyl-primed triketide and
tetraketide pyrones as byproducts. This work provides important information about the PKS
involved in the biosynthesis of spirolaxine, which will facilitate further understanding and
engineering of the biosynthetic pathway of this medicinally important molecule.

*This chapter has been published as Sun, L., Wang, S., Zhang, S., Yu, D., Qin, Y., Huang, H., Wang, W.*, Zhan, J.*
(2016): Identification of a type III polyketide synthase involved in the biosynthesis of spirolaxine. Applied
Microbiology and Biotechnology 100(16), 7103–7113.
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4.1 Introduction
Fungi produce numerous structurally and functionally diverse natural products. Some fungal
metabolites have been developed into therapeutics such as penicillin (antibacterial) and lovastatin
(anti-cholesterol), while others have shown interesting biological activities and may represent
promising lead compounds for new drug development. Spirolaxine (5, Fig. 19) is a natural product
originally discovered from Sporotrichum laxum ATCC® 15155 (Basidiomycetes) as a plant growth
inhibitor [1]. It was later found to possess significant anti-Helicobacter pylori activity,
representing a potential drug candidate for the treatment of H. pylori-related diseases [2]. 5 was
also reported to exhibit cholesterol-lowering activity [3]. A more recent research reported that 5
has inhibitory activities towards endothelial cells (BMEC and HUVEC) and a variety of tumor cell
lines (i.e., LoVO and HL60) [4-6]. Besides 5, two other 5,5-spiroacetal phthalides, CJ-12,954 (13)
and CJ-13,014 (14), were also isolated from the cultures of the basidiomycete Phanerochaete
velutina. All these molecules showed anti-H. pylori activity [7], while 5 showed twice as much
potency as the other two spiroacetal compounds 13 and 14.

Fig. 19 Structures of spirolaxine and analogs.
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Compound 5 belongs to a group of interesting secondary metabolites that feature a unique 3methoxy-5-hydroxy-phthalide nucleus linked to a 6,5-spiroacetal group through a five-membered
methylene chain. Owing to the interesting biological activities and structural characteristics, the
structures of these compounds were determined and many efforts were devoted to the development
of a chiral synthetic route of 5 and its derivatives [8, 9]. However, it remains unknown how 5 is
assembled by particular biosynthetic enzymes in the producing host. In our previous research, we
proposed that a linear polyketide intermediate synthesized by a highly reducing polyketide
synthase (HR-PKS) is taken by a non-reducing polyketide synthase (NR-PKS) as the starter unit
and extended through three rounds of decarboxylative condensation of malonyl-CoA. The
polyketide backbone undergoes subsequent C-2/C-7 and C-1/C-8 cyclizations. The formed
phthalide core structure is then released from the enzyme and further modified by a series of
tailoring enzymes to yield 5 [9]. This proposed route is similar to the formation of the family of
fungal benzenediol lactone (BDL) polyketides such as radicicol and dehydrocurvularin [10-13].

On the other hand, fungal type III PKSs are found to synthesize akylresorcinols [14], which
may also serve as the biosynthetic precursor of 5 for a series of tailoring reactions. Filamentous
fungi are a known source of natural products with wide applications in agriculture, medicine,
industry, and nutrition. Since the discovery of the first fungal type III PKS ORAS from Neurospora
crassa [15], several fungal type III PKSs have been reported. For example, Aspergillus niger
AnPKS [16] catalyzes the synthesis of pentaketide alkylresorcylic acids, while BPKS from
Botrytis cinerea accepts C4-C18 aliphatic acyl-CoAs and benzoyl-CoA as the starters to form
pyrones, resorcylic acids and resorcinols through sequential condensation with malonyl-CoA [17].
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CsyA from A. oryzae synthesizes triketide and tetraketide pyrones [18], and CsyB from the same
strain takes a starter fatty acyl-CoA, malonyl-CoA and acetoacetyl-CoA to synthesize 3-acetyl-4hydroxy-6-alkyl-α-pyrone [19].

To understand the biosynthetic process of 5, the genomic DNA of S. laxum ATCC® 15155 was
sequenced in this work. However, analysis of the genomic sequence did not yield any pair of HRPKS and NR-PKS that are proposed to synthesize 5. Instead, we found two putative type III PKS
genes, Sl-pks1 (GenBank accession no. KU560626) and Sl-pks2 (GenBank accession no.
KU560627), which are located adjacent to each other in a tail-to-tail arrangement. Knockout of Slpks1 has no effects on spirolaxine biosynthesis, whereas disruption of Sl-pks2 abolished the
production of 1, which thus revealed that Sl-PKS2 is a dedicated PKS involved in the biosynthesis
of 5. This enzyme was functionally characterized as an alkylresorcinol synthase through in vitro
enzymatic reactions and isolation of in vivo products from the heterologous host Escherichia coli.

4.2 Materials and Methods

4.2.1 General method
Polyketide products were detected and isolated on an Agilent 1200 high performance liquid
chromatography (HPLC) instrument. Electrospray ionization mass spectrometry (ESI-MS) spectra
were collected on an Agilent 6130 Single quadrupole LC-MS. Nuclear magnetic resonance (NMR)
spectra were acquired in CDCl3 on a JEOL NMR instrument (300 MHz for 1H NMR and 75 MHz
for 13C NMR). The chemical shift (δ) values were given in parts per million (ppm). The coupling
constants (J values) were reported in Hertz (Hz).
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4.2.2 Strains and materials
DNA manipulations were performed using standard techniques with Escherichia coli XL1Blue as a host organism. Expression vector pET28a was purchased from Novagen (Madison, WI,
USA). E. coli BL21-CodonPlus (DE3)-RIL was purchased from Stratagene (La Jolla, CA, USA)
as the expression host. S. laxum strain ATCC® 15155 was obtained from the American Type
Culture Collection. Malonyl-CoA was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Straight-chain saturated fatty acyl-SNACs (N-acetylcysteamine thioesters) were synthesized as
previously described [18].

4.2.3 Extraction and sequencing of genomic DNA
S. laxum was cultured in 50 mL of potato dextrose broth (PDB) at 28 C for 4 days, and the
genomic DNA was extracted using the method as described before [18]. The genome was then
sequenced using an Illumina MiSeq desktop sequencer and assembled with the short read de novo
assembler Velvet. Augustus was used for gene prediction [20], and BLASTX was used for
annotation. FramePlot [21] was used to analyze the predicted PKS genes, with Phanerochaete
chrysosporium transcriptome as the reference.

4.2.4 Knockout of Sl-pks2 and Sl-pks1 from S. laxum
The genomic DNA of S. laxum was used as the template to amplify a 2.7-kb fragment
upstream Sl-pks2 (left arm) with a set of specific primers Sl-PKS2-ko-la-F and Sl-PKS2-ko-la-R
(Table 9). Similarly, a 3.0-kb downstream fragment (right arm) was amplified with another set of
primers Sl-PKS2-ko-ra-F and Sl-PKS2-ko-ra-R (Table 9). The PCR products were first ligated to
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the cloning vector pJET1.2 to yield pSUN56 and pSUN55, respectively (Table 10). After the
plasmids were sequenced, the inserts were subsequently cloned into the pAg1-H3 vector to yield
pSUN63 (Table 10).

Table 9 List of primers used in Chapter IV. *
Primers
Sl-PKS2-F
Sl-PKS2-R
Sl-PKS1-ko-la-F
Sl-PKS1-ko-la-R
Sl-PKS1-ko-ra-F
Sl-PKS1-ko-ra-R
Sl-PKS2-ko-la-F
Sl-PKS2-ko-la-R
Sl-PKS2-ko-ra-F
Sl-PKS2-ko-ra-R
Sl-PKS1-ko-la-check-F
Sl-PKS1-ko-ra-check-R
HYG-check-F
HYG-check-R
Sl-PKS2-ko-la-check-F
Sl-PKS2-ko-ra-check-R

Sequence
5'-CGGGATCCATGTCTCCCGCAAAGCTC-3'
5'-CGGAATTCTTACCCCGAGTCAGAGGAACC-3'
5'-GGGGTACCCTCACCCAGAATGCACTGGTC-3'
5'-GGCCTAGGGATTTTGGGTAGCGCCTTTG-3'
5'-GGACTAGTCAGGGAAAGGAGGCCGG-3'
5'-GGTTAATTAACAGGCGCTCGAGGGAAAC-3'
5'-AGCCCGGGTTGGCG-3'
5'-GGCCTAGGAGCGGTAGGAGGACAGTCGAG-3'
5'-GGACTAGTACCCCAGATCGAATGATTATCTAC-3'
5'-GGTTAATTAACTACAAAACCGAATTCGACTCTACAC-3'
5'-GGTGGATAGCGTGCCATC-3'
5'-GGGAGCGAGCGCACTC-3'
5'-AGCTTGACTATGAAAATTCCGTCAC-3'
5'-CGGAGACGCTGTCGAACTTT-3'
5'-GGTGCTGACGATCTCGGAG-3'
5'-CACAAACTACGTATCATTGAAGCATG-3'

Restriction sites
BamHI
EcoRI
KpnI
AvrII
SpeI
PacI
SmaI
AvrII
SpeI
PacI

* The restriction sites are underlined.

To disrupt Sl-pks1, the two arms (3.0 kb and 3.5 kb) were amplified with two sets of primers
including Sl-PKS1-ko-la-F, Sl-PKS1-ko-la-R, Sl-PKS1-ko-ra-F and Sl-PKS1-ko-ra-R (Table 9).
Ligation of the two arms into pJET1.2 yielded pSUN106 and pSUN107, respectively (Table 10).
The disruption plasmid pSUN110 (Table 10) was obtained after the two arms were cloned into
pAg1-H3.
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Table 10. List of plasmids constructed in Chapter IV.
Plasmids
pSUN24
pSUN26
pSUN55
pSUN56
pSUN63
pSUN106
pSUN107
pSUN110

Description
Sl-pks2 (from cDNA) in pJET1.2
Sl-pks2 (from cDNA) in pET28a
right arm for Sl-pks1 knockout in pJET1.2
left arm for Sl-pks1 knockout in pJET1.2
right arm-HYG-left arm in pAG1-H3 for Sl-pks1 knockout
right arm for Sl-pks2 knockout in pJET1.2
left arm for Sl-pks2 knockout in pJET1.2
right arm-HYG-left arm in pAG1-H3 for Sl-pks2 knockout

The two disruption plasmids, pSUN63 and pSUN110, were respectively electroporated
transformed into Agrobacterium tumefaciens LBA4404 strain, which carries the pAL4404 Ti
plasmid. This plasmid only has the vir and ori regions of the Ti plasmid. Electroporation
conditions were 25 μF, 200 Ω, 2.5 kV (0.2 cm cuvettes) on a Gene Pulser® electroporator (BioRad, USA).

A. tumefaciens LBA4404 cells containing the T-DNA binary vectors were grown overnight at
28 °C in YM broth (yeast extract 0.4 g L -1, mannitol 10 g L-1, NaCl 0.1 g L-1, MgSO4 0.1 g L-1,
K2HPO4·3H2O 0.5 g L-1, pH 7.0) containing 50 μg mL−1 kanamycin. Subsequently, 1 mL of the
culture was centrifuged at 3,500 rpm for 5 min. The pelleted cells were washed twice with 1 mL
of induction medium (IM) (K2HPO4 3 g L−1, NaH2PO4 1 g L−1, (NH4)2SO4 0.5 g L−1, MgSO4·7H2O
0.3 g L−1, KCl 0.15 g L−1, CaCl20.005 g L−1, FeSO4·7H2O 0.0025 g L−1, glucose 10 mM, 2-[Nmorpholino] ethanesulphonic acid (MES) 40 mM, glycerol 0.5% (w/v), pH 5.3), inoculated in 50
mL of fresh IM, and grown for an additional 5 hr at 28 °C. The final OD600 value of the cultures
should be around 0.5. Before co-cultivation, the cells were washed twice as described above with
an equal volume of sterile 0.85% NaCl (w/v) solution and re-suspended in 1mL of 0.85% NaCl.
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S. laxum was incubated on potato dextrose agar plates at 28 C for 5 days to allow spores
germination. Spores were washed with sterile 0.85% NaCl (w/v) solution and re-suspended with
1 mL of above-prepared A. tumefasciens cells. The mixture was inoculated onto sterile cellulose
films and applied over IM-agar plates containing 500 nM acetosyringone (AS) and incubated at
25 C for 24 hr. After co-cultivation, the films that have both S. laxum and A. tumefasciens were
transferred to a new batch of IM-agar plates containing 250 μg mL−1 hygromycin B and 100 μg
mL−1 ampicillin for colony selection and inhibition of A. tumefaciens LBA4404. The plates were
incubated at 28 C for 7 days until the single colonies appeared.

To confirm the deletion of gene Sl-pks2 in S. laxum, we extracted the genomic DNA of S.
laxum mutants with ZR Fungal/Bacterial DNA MiniPrep TM (ZYMO Research, CA, USA). Two
pairs of check primers, including the genome-specific primers Sl-PKS2-ko-la-check-F and SlPKS2-ko-ra-check-R as well as the vector-specific primers HYG-check-F and HYG-check-R (lied
in the hygR gene) (Table 9) were used to amplify two specific fragments from the mutant. For
analyzing the deletion of Sl-pks1, the genome-specific primers Sl-pks1-la-check-F and Sl-pks2-racheck-R were used the vector-specific primers (Table 9).

4.2.5 Amplification of intron-free Sl-pks2 from the cDNA of S. laxum and construction of pET28aSl-pks2
Wild type S. laxum was grown in PDB at 28 C for 3 days. The cells were harvested by
filtration, from which the RNA was extracted with TRIzol Reagent (Invitrogen, USA). The
extracted RNA was purified with a Direct-zol RNA MiniPrep kit (Zymo Research, CA, USA). The
cDNA was synthesized from total RNA with M-MuLV Reverse Transcriptase (NEB, MA, USA).
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With the cDNA as a template, a 1,227-bp DNA fragment of the intron-free Sl-pks2 gene was
amplified

by

PCR

with

a

set

of

specific

primers

including

Sl-PKS2-F

(5'-

CGGGATCCATGTCTCCCGCAAAGCTC-3', with a BamHI site shown by underlining) and SlPKS2-R (5'-CGGAATTCTTACCCCGAGTCAGAGGAACC-3', with an EcoRI site shown by
underlining). The resulting intron-free fragment was cloned into the pJET1.2 cloning vector, and
subsequently cloned into pET28a vector between the BamHI and EcoRI sites, resulting in pSUN26.

4.2.6 In vivo polyketide biosynthesis
E. coli BL21-CodonPlus (DE3)-RIL cells harboring pET28a-Sl-pks2 were grown in LuriaBertani (LB) broth containing 50 μg mL -1 kanamycin and 50 μg mL-1 chloramphenicol at 37°C
and 250 rpm. Until the OD600 reached 0.6, 200 μM isopropyl-β-D-1-thiogalactopyranoside (IPTG)
was added to induce the overexpression of Sl-PKS2. The induced broth was maintained at 28 °C
and 250 rpm for an additional 24 hr. The cells were harvested by centrifugation at 3,500 rpm for
5 min. Polyketide products were extracted from both the supernatant with ethyl acetate and the
pellet with methanol. The organic extracts were combined and concentrated in rotavapor to an oily
residue. The extract was analyzed on an Agilent 1200 HPLC instrument (Agilent Eclipse Plus C18,
5 μm, 4.6 mm × 250 mm), eluted with a linear gradient of 75 to 90 % (v/v) acetonitrile-water
(containing 0.1% trifluoroacetic acid) over 45 min at a flow rate of 1 mL min−1. The products were
detected at 280 nm.

4.2.7 Purification and structural characterization of alkylresorcinols 16-20
To isolate compounds 16-20 for structural characterization, the culture was scaled up to 1 L
and grown for 72 h. Briefly, 1 mL of seed culture (OD 600=1.0) of E. coli BL21-CodonPlus (DE3)-
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RIL/pET28a-Sl-pks2 was inoculated into 1 L of LB medium containing 50 μg mL−1 kanamycin
and chloramphenicol, and grown to OD600 of 0.6. 200 µM IPTG was then added to induce protein
expression. After fermentation, the culture was extracted as described above. To isolate these
compounds, a typical purification procedure was given below. The crude extract was fractionated
on a silica gel-60 column, eluted with a stepwise gradient of ethyl acetate-hexane (0:100, 1:99,
2:98, 3:97, 5:95, 10:90, 15:85, 20:80 v/v, each 250 mL) to afford 8 fractions. The fractions
containing the target compounds were further separated by reverse-phased HPLC (Agilent Eclipse
Plus C18, 5 μm, 4.6 mm × 250 mm), eluted with acetonitrile-water at a flow rate of 1 mL min−1.
Compound 16 was found to be in fraction 6 after silica gel column chromatography. This fraction
was further separated on HPLC with 67% acetonitrile-water. The peak at 23.7 min was collected
to yield 5.1 mg of 16 in pure form. Compounds 17 and 18 were found to be in fraction 5 after silica
gel column chromatography. This fraction was further separated on HPLC with 74% acetonitrilewater. The peaks at 32.4 min and 35.6 min were collected to yield 6.4 mg of 17 and 8.1 mg of 18,
respectively, in pure form. Compounds 19 and 20 were found to be in fraction 3 after silica gel
column chromatography. This fraction was further separated on HPLC with 82% acetonitrilewater. The peak at 47.9 min and 50.5 min were collected to yield 10.1 mg of 19 and 9.4 mg of 20,
respectively.

Compound 16: ESI-MS (+): [M+H]+ m/z 291; lH NMR (300 MHz, CDC13): δ 6.24 (2H, d, J =
1.8 Hz, H-4 and H-6), 6.19 (1H, t, J = 1.8 Hz, H-2), 5.34-5.36 (2H, m, H-6' and H-7'), 2.49 (2H, t,
J = 7.5 Hz, H-1'), 2.01 (4H, m, H-5' and H-8'), 1.57 (2H, m, H-2'), 1.31 (approx. 12H, m), 0.89
(3H. t, J = 6.9 Hz, H-13'). 13C NMR (75 MHz, CDCl3): δ 156.8 (C-1 and C-3), 146.3 (C-5), 130.0
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and 130.2 (C-6' and C-7'), 108.2 (C-4 ad C-6), 100.4 (C-2), 36.0 (C-l'), 32.0, 31.3 (C-2'), 30.0-29.2
(m), 27.4, 22.9, 14.3 (C-13').

Compound 17: ESI-MS (+): [M+H]+ m/z 293; lH NMR (300 MHz, CDC13): δ 6.25 (2H, d, J
= 1.8 Hz, H-4 and H-6), 6.20 (1H, t, J = 1.8 Hz, H-2), 2.47 (2H, t, J = 7.5 Hz, H-1'), 1.55 (2H, m,
H-2'), 1.31 (approx. 20H, brs), 0.89 (3H. t, J = 6.9 Hz, H-15'). 13C NMR (75 MHz, CDCl3): δ 156.8
(C-1 and C-3), 146.4 (C-5), 108.2 (C-4 and 6), 100.3 (C-2), 36.0 (C-l'), 32.1, 31.3 (C-2'), 29.929.5 (m), 27.4, 22.9 (s), 14.3 (C-13').

Compound 18: ESI-MS (+): [M+H]+ m/z 319; lH NMR (300 MHz, CDC13): δ 6.25 (2H, d, J
= 1.8Hz, H-4 and H-6), 6.20 (1H, t, J = 1.8 Hz, H-2), 5.34-5.36 (2H, m, H-8' and H-9'), 2.48 (2H,
t, J = 7.5 Hz, H-1'), 2.03 (4H, m, H-7' and H-10'), 1.56 (2H, m, H-2'), 1.29 (approx. 16H, brs), 0.88
(3H, t, J = 6.9 Hz, H-15'). 13C NMR (75 MHz, CDCl3): δ 156.9 (C-1 and C-3), 146.4 (C-5), 130.2
(C-8' and C-9'), 108.3 (C-4 and C-6), 100.4 (C-2), 36.1 (C-l'), 32.2, 32.3 (C-2'), 30.0-29.3 (m),
27.4, 22.9, 14.3 (C-15').

Compound 19: ESI-MS (+): [M+H]+ m/z 321; lH NMR (300 MHz, CDC13): δ 6.25 (2H, d, J
= 1.8 Hz, H-4 and H-6), 6.20 (1H, t, J = 1.8 Hz, H-2), 2.48 (2H, t, J = 7.5 Hz, H-1'), 1.58 (2H, m,
H-2'), 1.29 (approx. 24H, brs), 0.89 (3H, t, J = 6.9 Hz, H-15'). 13C NMR (75 MHz, CDCl3): δ 157.0
(C-1 and C-3), 146.3 (C-5), 108.1 (C-4 and C-6), 100.3 (C-2), 36.1 (C-l'), 32.1, 32.0 (C-2'), 29.929.5 (m), 27.4, 22.9, 14.3 (C-15').
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Compound 20: ESI-MS (+): [M+H]+ m/z 347; lH NMR (300 MHz, CDC13): δ 6.25 (2H, d, J
= 1.8 Hz, H-4 and H-6), 6.20 (1H, t, J = 1.8 Hz, H-2), 5.35-5.36 (2H, m, H-10' and H-11'), 2.49
(2H, t, J = 7.5 Hz, H-1'), 2.03 (4H, m, H-9' and H-12'), 1.57 (2H, m, H-2'), 1.29 (approx. 20H, brs),
0.88 (3H, t, J = 6.9 Hz, H-17'). 13C NMR (75 MHz, CDCl3): δ 156.9 (C-1 and C-3), 146.3 (C-5),
130.2 and 130.0 (C-10' and C-11'), 108.2 (C-4 and C-6), 100.4 (C-2), 36.0 (C-l'), 32.0, 31.3 (C-2'),
30.0-29.2 (m), 27.4, 22.9, 14.3 (C-17').

4.2.8 Production and purification of His6-tagged Sl-PKS2
For production of His6-tagged Sl-PKS2, E. coli BL21-CodonPlus (DE3)-RIL harboring
pET28a-Sl-pks2 was grown at 18 °C in Luria-Bertani (LB) broth containing 50 μg mL-1 kanamycin
and 50 μg mL-1 chloramphenicol. When the OD 600 reached 0.6, 200 μM isopropyl β-d-1thiogalactopyranoside (IPTG) was added to induce the expression of Sl-PKS2. The induced culture
was maintained at 28 °C for an additional 16 h. Cells were harvested by centrifugation,
resuspended in the lysis buffer composed of 20 mM Tris-HCl (pH 7.9) and 0.5 M NaCl, and
disrupted by sonication. A crude cell-lysate was prepared by centrifugation at 13,000 rpm at 4 °C
for 15 min to remove cell debris. N-His6-tagged Sl-PKS2 was purified using nickel-nitrilotriacetic
acid (Ni-NTA) agarose (Qiagen, Valencia, CA, USA) according to the manual from the
manufacturer. The purified His6-tagged protein was concentrated and desalted against buffer A
[50 mM Tris-HCl (pH 7.9), 2 mM ethylenediaminetetraacetic acid (EDTA) and 1 mM
dithiothreitol (DTT)] with a centrifugal filter device (Millipore, Billerica, MA, USA).

4.2.9 PKS assay
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A typical reaction mixture contained 200 μM malonyl-CoA, 100 μM acyl-SNAC, 100 mM
phosphate buffer (pH 7.0), and 10 μg of Sl-PKS2 in a total volume of 100 μL. Reaction was
incubated at 30 °C for 60 min before being quenched with 50 μL of methanol. The samples were
centrifuged at 15,000 rpm for 5 min and the products in the supernatant were analyzed on an
Agilent 1200 HPLC instrument (Agilent Eclipse Plus C18, 5 μm, 4.6 mm × 250 mm). The samples
were eluted with a linear gradient of 30 to 90% (v/v) acetonitrile-water (containing 0.1%
trifluoroacetic acid) over 45 min at a flow rate of 1 mL min −1, and the compounds were detected
at 280 nm. The identity of the synthesized products was determined by the comparison of the
retention times and UV absorptions with those of the products previously reported [18], which was
further confirmed by the mass spectra measured on an Agilent 6130 quadrupole LC-MS.

4.3 Results

4.3.1 Discovery and analysis of two putative type III PKS genes from S. laxum
Sporotrichum laxum is a producer of 5. The genome of this strain was sequenced. A total of
11,347 proteins were predicted by Augustus, which are compared with the NCBI nonredundant
(NR) protein databases by BLASTX to predict their biological functions. The sequenced data were
further analyzed using a gene annotation tool FramePlot with Phanerochaete chrysosporium
transcriptome as the reference. Two putative chalcone synthase (CHS)-like type III PKS genes, Slpks1 and Sl-pks2, are arranged tail to tail on the genome, separated only by a region of ~2.0 kb.
BLAST analysis of the primary amino acid sequences of the deduced proteins yielded a lot of
homologs from the CHS superfamily enzymes, although the closest homologs to Sl-PKS1 and SlPKS2 are two unidentified proteins (XP_007391993.1, 85% identity and XP_007391992.1, 72%
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identity) from Phanerochaete carnosa HHB-10118-sp. Sequence alignment of Sl-PKSs with N.
crassa ORAS [15] and A. oryzae CsyA revealed that both S. laxum Sl-PKSs maintain an almost
identical CoA binding site with the reported type III PKSs and a conserved catalytic triad of Cys158, His-312, and Asn-345 (numbering in Sl-PKS2) (Fig. 20).

*

*

*

Fig. 20 Amino acid sequence alignment of Sl-PKS1, Sl-PKS2, ORAS and CsyA. The conserved
Cys-His-Asn catalytic triad is asterisked.

4.3.2 Knockout of Sl-pks1 and Sl-pks2 from S. laxum
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To determine whether Sl-PKS1 and Sl-PKS2 are involved in spirolaxine biosynthesis, targeted
gene knockout was performed, respectively. A disruption vector pAg1-H3 (Fig. 21 A) containing
a hygromycin phosphotransferase B gene (HYG) cassette flanked with the 3.0-kb left arm and 3.5kb right arm for Sl-pks1 knockout. The left and right arms were gene fragments upstream and
downstream of the target gene on the genome of S. laxum. Similarly, a 2.7-kb left arm and a 3.0kb right arm are used for the knockout of Sl-pks2. The products of wild type S. laxum and the two
mutants were analyzed by HPLC. As shown in Fig. 21 B, the wild type (trace i) produced two
major compounds on WSH plates including 5 at 34.1 min and its analogue sporotricale (15) at 24.2
min. Knockout of Sl-pks1 did not affect the product profile and the two major products were still
generated (trace ii), suggesting that this gene is not involved in the biosynthesis of these
compounds. In contrast, the Sl-pks2 knockout mutant of S. laxum failed to produce these
compounds (trace iii). Genomic DNA of the knockout mutants was extracted and used as the
template for PCR amplification to check whether the target genes were deleted. Genome- and
vector-specific primers (Table 7) were used. For the S. laxum-Sl-pks2 mutant, a 3.0-kb fragment
(lane 1, Fig. 21 C) was amplified from the upstream region of the disruption site using the genomespecific primer Sl-pks2-la-check-F and the vector-specific primer HYG-check-R. Similarly, a
downstream fragment (4.2 kb, lane 2) was obtained using HYG-check-F and Sl-pks2-ra-check-R.
No products were amplified from the genome of the wild type (lanes 3 and 4), which confirmed
that the loss of spirolaxine production was a consequence of the targeted gene replacement of Slpks2. Knockout of Sl-pks1 was verified in the same way. Two fragments (4.4 kb, lane 5, and 3.3
kb, lane 6) were amplified from the mutant, but not the wild type, further confirming that Sl-PKS1
is not involved in spirolaxine biosynthesis. Thus, Sl-PKS2 is a dedicated PKS involved in the
biosynthesis of 5.
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Fig. 21 Gene disruption of Sl-pks1 and Sl-pks2. (A) Double crossover strategy to disrupt Sl-pks1
and Sl-pks2. pAG-H3 and hygromycin were used as the vector and selection marker, respectively.
(B) HPLC analysis of the products of wild type S. laxum (i), S. laxum-Sl-pks1 (ii) and S. laxumSl-pks2 (iii). (C) Verification of the correct knockout mutants. Genome-specific check primers
(Sl-PKS1-ko-la-check-F, Sl-PKS1-ko-ra-check-R, Sl-PKS2-ko-la-check-F and Sl-PKS2-ko-racheck-R) and vector-specific primers HYG-check-F and Hyg-check-R were used to amplify
particular fragments from the mutants, while no products were obtained from the wild type using
the same sets of primers. M: 1 kb Plus DNA ladder; 1: a 3.0-kb fragment upstream the disruption
site of Sl-pks2 amplified from S. laxum-Sl-pks2 with Sl-PKS2-ko-la-check-F and HYG-check-R;
2: a 4.2-kb fragment downstream the disruption site of Sl-pks2 amplified from S. laxum-Sl-pks2
with HYG-check-F and Sl-PKS2-ko-ra-check-R; 3: no product from wild type S. laxum with SlPKS2-ko-la-check-F and HYG-check-R; 4: no product from wild type S. laxum with HYG-checkF and Sl-PKS2-ko-ra-check-R; 5: a 4.4-kb fragment upstream the disruption site of Sl-pks2
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amplified from S. laxum-Sl-pks1 with Sl-PKS1-ko-la-check-F and HYG-check-R; 6: a 3.3-kb
fragment downstream the disruption site of Sl-pks1 amplified from S. laxum-Sl-pks1 with HYGcheck-F and Sl-PKS1-ko-ra-check-R; 7: no product from wild type S. laxum with Sl-PKS1-ko-lacheck-F and HYG-check-R; 8: no product from wild type S. laxum with HYG-check-F and SlPKS1-ko-ra-check-R.

4.3.3 Characterization of the products synthesized by Sl-PKS2 in E. coli
Having investigated the Sl-pks2 knockout strain, we further examined whether Sl-PKS2 can
be expressed in a heterologous host such as E. coli to produce corresponding polyketide products.
Fatty acyl-CoAs or -ACPs, naturally present in E. coli, are the intermediates in fatty acid
biosynthesis or metabolism. In our previous research, A. oryzae type III PKS CsyA was found to
take these starter units to synthesize alkylpyrones in E. coli [18]. In E. coli, fatty acids are
assembled by fatty acid synthases from acetyl-CoA and malonyl-CoA. These fatty acyl-ACPs (or
CoAs) could be accepted as starters for condensation reactions catalyzed by PKSs with abroad
starter flexibility, such as the type I PKS Gibberella zeae PKS13 [22] and type III PKS CsyB [19].
We have previously isolated 5 and analogs as well as alkylresorcylic acids from S. laxum. These
compounds feature a C16 or C18 fatty acyl side chain attached to a benzene ring [9]. Thus, we
hypothesized that Sl-PKS2 can accept various acyl-ACPs or acyl-CoAs as starter units that are
available in E. coli [23]. We amplified the intron-free Sl-pks2 (1,243 bp) gene from the cDNA of
S. laxum (Fig. 22 A), and ligated the gene with the expression vector pET28a to yield pSUN26,
which was used to transform E. coli BL21-CodonPlus (DE3)-RIL. The IPTG-induced broth was
extracted with an equal volume of ethyl acetate. As shown in Fig. 22 B, HPLC analysis revealed
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that five major products (16-20, trace i) were synthesized by Sl-PKS2, which were not present in
E. coli BL21-CodonPlus (DE3)-RIL-pET28a (trace ii) that was used as negative control.

These five products were isolated from the scaled-up culture of E. coli BL21-CodonPlus
(DE3)-RIL-pSUN26. Compounds 16-29 were obtained as yellowish oil. These compounds were
identified as alkylresorcinols with either an unsaturated or saturated aliphatic side chain (Fig. 22
C) based on their, UV, MS and NMR spectra and a comparison with previously published data
[24]. The molecular weights of 16-20 were determined to be 290, 292, 318, 320 and 346 based on
their [M+H]+ ion peaks at m/z 291, 293, 319, 321 and 347 in the ESI-MS, respectively.
Accordingly, compounds 17 and 19 were deduced to be alkylresorcinols with a saturated side chain,
while 16, 18 and 20 have an unsaturated side chain. The 1H and 13C NMR spectra of 17 revealed
two aromatic proton signals at δH 6.25 (2H, d, J = 1.8 Hz, H-4 and H-6) and δH 6.20 (1H, t, J = 1.8
Hz, H-2), and four carbon signals at δC 100.3 (C-2), 108.2 (C-4 and C-6), 146.4 (C-5), and 156.8
(C-1 and C-3), suggesting that a resorcinol moiety is present in the structure. In addition, proton
signals typical for a long aliphatic chain including the benzylic methylene at δ H 2.47 (2H, t, J =
7.5 Hz) and terminal methyl group at δ H 0.89 (3H, t, J = 6.9 Hz) were also found. Thus, 17 was
identified as 1,3-dihydroxyphenyl-5-tridecane, a resorcinol derivative with a saturated C13 side
chain. 19 has highly similar NMR data to those of 17, but has an additional CH2-CH2 unit. Thus,
it was characterized as 1,3-dihydroxyphenyl-5-pentadecane that has a saturated C15 side chain. The
NMR spectra of 16 also showed the aromatic proton and carbon signals which are similar to 17.
However, two overlapping olefinic protons at δ H 5.34-5.36 and carbon signals at δC 130.0 indicated
that there is a double bond in the side chain. Thus, 16 was characterized as 1,3-dihydroxyphenyl5-cis-6'-tridecene. Similarly, 18 and 20 were identified as resorcinol derivatives containing an
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unsaturated C15 and C17 side chain, named 1,3-dihydroxyphenyl-5-cis-8'-pentadecene and 1,3dihydroxyphenyl-5-cis-10'-heptadecene, respectively. These data were in good agreement with the
data reported previously for 5-alk(en)ylresorcinols [24, 25]. The thioesters of common fatty acids
in E. coli [26, 27] are proposed to be used by Sl-PKS2 as the starter units to synthesize 16-20.
Specifically, the thioesters of unsaturated fatty acids including tetradecenoic acid (cis-7),
hexadecenoic acid (cis-9), and octadecenoic acid (cis-11) are used by Sl-PKS2 to afford 16, 18
and 20, while the thioesters of myristicacid (C14:0) and palmitic acid (C16:0) were used to
synthesize 17 and 19, respectively.

Fig. 22 Expression of intron-free Sl-pks2 in E. coli BL21-CodonPlus (DE3)-RIL and analysis of
the in vivo polyketide products. (A) Amplification of the Sl-pks2 gene from the cDNA and genomic
DNA. M: 1 kb Plus DNA ladder, 1: intron-free Sl-pks2; 2: intron-containing Sl-pks2. (B) HPLC
analysis of the products of ethyl acetate extracts of the cultures of E. coli BL21-CodonPlus (DE3)RIL-pSUN26 (trace i) and E. coli BL21-CodonPlus (DE3)-RIL-pET28a (trace ii). Five major
products 16-20 were detected. (C) The structures of alkylresorcinols 16-20.
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4.3.4 Functional characterization of Sl-PKS2 through in vitro reactions
His6-tagged Sl-PKS2 was purified (final yield 15 mg L-1) through Ni-NTA chromatography
for the in vitro reactions. The purified protein showed a single protein band at ∼43 kDa on SDSPAGE (Fig. 23 A). In order to test whether fatty acyl-CoAs are appropriate starter units for SlPKS2, we synthesized the SNAC esters of C6-C10 fatty acids (C6, C7, C8, C9 and C10) to mimic the
corresponding CoA esters. These starter units were respectively reacted with Sl-PKS2, with
malonyl-CoA as the extender substrate. HPLC analysis of the reactions revealed that Sl-PKS2 has
broad substrate specificity toward SNAC starters containing fatty acyl groups ranging from C 6 to
C10 (Fig. 23 B). For these starter units, Sl-PKS2 yielded three groups of product, and the retention
times of the products were consistent with the chain length. As observed in Fig. 23 B, the shorter
the chain length of the starters, the shorter the retention times of the resulting products on reversedphase HPLC. The peaks (groups a and b) have the UV absorption maximum at 204 and 286 nm,
which is characteristic UV absorbance pattern for pyrones. Through LC-MS analysis and a
comparison with the pyrone compounds we previously reported [18], we characterized the
products as fatty acyl-primed triketide (group a, 6a-10a, Fig. 23 C) and tetraketide pyrones (group
b, 6b-10b, Fig. 23 C). In contrast, group c compounds (6c-10c, Fig. 23 C) showed the maximum
UV absorptions at 203, 232 and 278 nm, which are consistent with alkylresorcinols we obtained
from E. coli. Further LC-MS allowed us to determine the length of the side chains in these 5alkylresorcinols. The pathways leading to the formation of these in vitro products are summarized
in Fig. 23 C.
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Fig. 23 Purification of Sl-PKS2 from E. coli BL21-CodonPlus (DE3)-RIL and in vitro reactions.
(A) SDS-PAGE analysis of the purification of Sl-PKS2. M: Protein ladder; 1: cell lysate; 2:
purified Sl-PKS2. (B) HPLC analysis of in vitro reactions of Sl-PKS2 with various acyl-SNACs
(C6-C10) and malonyl-CoA. i: hexanoyl-SNAC (C6); ii: heptanoyl-SNAC (C7); iii: octanoyl-SNAC
(C8); IV: nonanoyl-SNAC (C9); V: decanoyl-SNAC (C10). Three groups of product were formed,
including triketide pyrones 6a-10a, tetraketide pyrones 6b-10b, and alkylresorcinols 6c-10c. (C)
Summary of the in vitro reactions of Sl-PKS2.

4.3.5 Proposed biosynthetic pathway of spirolaxine
Type III PKSs are involved in the biosynthesis of many fungal natural products, such as
csypyrone B1 [19] and resorcinols [15]. Based on the functional characterization of Sl-PKS2 and
the metabolites we previously isolated from the host [9], a type III polyketide biosynthetic pathway
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was proposed to synthesize 5 (Fig. 24). Palmitoyl-CoA (21) or palmitoyl-ACP (22) was adopted
as the starter substrate by a type III PKS (Sl-PKS2), which elongates the chain using three
molecules of malonyl-CoA to yield a nascent polyketide chain 23. This intermediate is cyclized
via an intramolecular C-2/C-7 aldol condensation to form the intermediate 24. The regioselective
C-2/C-7 cyclization by the dedicating type III PKS is observed in the biosynthesis of various
natural products [15]. The polyketide intermediate can be hydrolyzed and released from the
enzyme to yield the resorcylic acid derivative 24. Hydroxylation of C-21 yielded 25. A ring is
formed between C-1 carboxyl and C-8 to yield the phthslide structure 26, which can be further
methylated at 3-OH to afford 27. 27 is subsequently hydroxylated at C-18 to yield 28, which is
oxidized and then cyclized to form the methyltetrahydrofuran ring to give rise to 29. A hydroxyl
group at C-14 was introduced to afford 30, which is then used to form the tetrahydropyran ring
and yield the final product spirolaxine (5). In our previous research, we isolated (R)-3,5-dihydroxy7-(16-hydroxyheptadecyl)benzoic acid and (R)-3,5-dihydroxy-7-(15-hydroxyheptadecyl)benzoic
acid from S. laxum [9], which indicated that Sl-PKS2 also can accept stearoyl-CoA (C18:0) as a
starter unit. This, together with the in vivo and in vitro results in this work, confirmed that Sl-PKS2
has broad substrate specificity toward acyl starter units.
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Fig. 24 Proposed biosynthetic pathway for spirolaxine (5). 5 is assembled by Sl-PKS2 and a series
of tailoring enzymes. The reaction sequence is not determined.

4.4 Conclusion
In this work, I identified Sl-PKS2 from S. laxum as a new fungal type III PKS which
synthesizes fatty acyl-primed resorcylic acid compounds. Our work demonstrated that Sl-PKS2
activities can be completely reconstituted both in vitro and in E. coli. The products of Sl-PKS2 in
E. coli are alkylresorcinols, which resulted from decarboxylation of corresponding alkylresorcylic
acids [15]. Consistently, in vitro reaction of Sl-PKS2 with various fatty acyl-SNACs yielded
corresponding alkylresorcinols as major products. Interestingly, triketide and tetraketide pyrones
were also found as minor products in these in vitro reactions. I also confirmed that Sl-PKS2 is
involved in the biosynthesis of the medicinally important compound spirolaxine, which for the
first time revealed that this molecule is assembled via a type III, instead of type I biosynthetic
pathway.
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CHAPTER V EFFECTS OF EXOGENOUS NUTRIENTS ON POLYKETIDE
BIOSYNTHESIS IN ESCHERICHIA COLI *

ABSTRACT
Heterologous hosts are important platforms for engineering natural product biosynthesis.
Escherichia coli is such a host widely used for expression of various biosynthetic enzymes. While
numerous studies have been focused on optimizing the expression conditions for desired functional
proteins, this work describes how supplement of exogenous nutrients into the fermentation broth
influences the formation of natural products in E. coli. A type III polyketide synthase gene stts
from Streptomyces toxytricini was heterogeneously expressed in E. coli BL21(DE3). This enzyme
uses five units of malonyl-CoA to generate a polyketide 1,3,6,8-tetrahydroxynaphthalene, which
can be spontaneously oxidized into a red compound flaviolin. In this work, we manipulated the
fermentation broth of E. coli BL21(DE3)/pET28a-stts by supplying different nutrients including
glucose and sodium pyruvate at different concentrations, from which six flaviolin derivatives 3136 were produced. While addition of glucose yielded the production of 31-34, supplement of
sodium pyruvate into the induced broth of E. coli BL21(DE3)/pET28a-stts resulted in the synthesis
of 35 and 36, suggesting that different nutrients may enable E. coli to generate different metabolites.
These products were purified and structurally characterized based on the spectral data, among
which 32-36 are novel compounds. These molecules were formed through addition of different
moieties such as acetone and indole to the flaviolin scaffold. The concentrations of glucose and
pyruvate and incubation time affect the product files. This work demonstrated that supplement of
nutrients can link certain intracellular metabolites to the engineered biosynthetic pathway to yield

*This chapter has been published as Sun, L.,# Zeng, J.,# Zhang, S., Gladwin, T., Zhan, J.* (2015): Effects of
exogenous nutrients on polyketide biosynthesis in Escherichia coli. Applied Microbiology and Biotechnology 99(2),
693–701. (# : equal contribution)
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new products. It provides a new approach to biosynthesizing novel molecules in the commonly
used heterologous host E. coli.

5.1 Introduction
Natural products are a major source of bioactive molecules that find applications in agriculture,
nutrition and medicine. Animals, plants and microorganisms produce a large variety of molecules.
These compounds are assembled by precisely programmed biosynthetic pathways in the hosts.
Polyketide compounds represent a large family of natural products which exhibit diverse
biological functions such as antitumor, antimicrobial and anti-cholesterol activities. Polyketides
are synthesized by the enzymes called polyketide synthases (PKSs). PKSs are classified into types
I, II and III according to different structures and mechanisms of these enzymes. Type I PKSs are
giant modular enzymes that consist of a series of catalytic domains [1], while type II PKSs are
discrete small enzymes that form multi-enzyme complexes to synthesize aromatic polyketides [2].
Type III PKSs are single enzymes that form homodimers, which contain single active site in each
monomer to catalyze the priming, extension, and cyclization reactions iteratively [3]. Recently,
our group has identified a new type III PKS StTS from Streptomyces toxytricini and reconstituted
it in E. coli [4]. This enzyme uses malonyl-CoA as the substrate to synthesize a polyketide product
1,3,6,8-tetrahydroxynaphthalene (THN), which can be spontaneously oxidized to form a red
compound flaviolin [4]. StTS is similar to the first reported bacterial type III PKS RppA [5]. Two
cytochrome P450 enzymes with the same function were also observed adjacent to stts in the
genome of S. toxytricini. The function of these P450s was believed to form dimers or trimers of
flaviolin [4, 6, 7]. Flaviolin is a red pigment that shows a strong protection of the hosts against UV
radiation [4, 8].
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Natural product biosynthesis has been extensively studied in recent years to facilitate the
understanding of biosynthetic mechanisms and pathway engineering for “unnatural” natural
products. While direct manipulation of biosynthetic genes in producing strains is often inaccessible
due to the lack of available genetic tools, several heterologous hosts have been developed for high
level expression of natural product biosynthetic enzymes, such as E. coli, Bacillus subtilis,
pseudomonads, S. cerevisiae, Streptomyces coelicolor, Streptomyces lividans, and Streptomyces
venezuelae [9-12]. E. coli is the most commonly used heterologous expression system, because it
has a mature system for genetic work and high efficiency for protein expression [13, 14]. This
system has been successfully used for the production of various bioactive molecules such as
echinomycin [15], oxytetracycline [16], δ-tocotrienol [17], and lyngbyatoxin [18]. To make E. coli
more efficient for natural product production, a lot of efforts have been put into engineering this
bacterium for increased supply of precursors and co-factors, as well as post-translational
modification of the expressed biosynthetic enzymes. For instance, the sfp phosphopantetheinyl
transferase gene was incorporated into the genome of E. coli BL21(DE3) to enable the activation
of acyl carrier proteins for polyketide biosynthesis [13]. Availability of NADPH has also been
increased by metabolic engineering to significantly improve the production of leucocyanidin and
(+)-catechin in E. coli [19]. These genetic manipulations have further made E. coli an attractive
heterologous host for natural product biosynthesis. However, it is not well understood how the
endogenous biosynthetic machinery of E. coli affects or interacts with the introduced heterologous
pathway. This work uses E. coli-StTS as a model system to demonstrate that addition of exogenous
nutrients such as glucose and pyruvate into the fermentation broth of engineered E. coli can lead
to the synthesis of “unexpected” new products. In addition to the original product flaviolin, a series
of novel flaviolin derivatives has been synthesized by the collaborative actions of StTS and the
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endogenous enzymes in the host through the incorporation of primary metabolites into the
polyketide skeleton. This work provides new insights into the effects of the primary metabolites
on engineered biosynthetic pathways in E. coli and thus affords a useful approach to creating
molecular diversity.

5.2 Materials and methods

5.2.1 General method
Polyketide products were analyzed and purified on an Agilent 1200 HPLC instrument. ESIMS spectra were acquired on an Agilent 6130 quadrupole LC-MS. NMR spectra were collected in
DMSO-d6 on a JEOL NMR instrument (300 MHz for 1H NMR and 75 MHz for 13C NMR). The
chemical shift () values are given in parts per million (ppm) and the coupling constants (J values)
are reported in Hertz (Hz).

5.2.2 Fermentation and product analysis
E. coli BL21(DE3) harboring pET28a-stts (pZJ93), which was constructed in our previous
work [4], was grown in 50 mL of Luria-Bertani (LB) medium containing 50 μg mL -1 kanamycin
at 37 C with shaking at 250 rpm. When the OD600 reached 1.0, 0.2 mM IPTG was added to induce
protein expression. The induced broths were cultured at 28 C for an additional 24 hr, and then
glucose or sodium pyruvate was added to the broths (0, 1, 5, or 10 mg mL-1, final concentration).
After fermentation, the culture broths were harvested by centrifugation. The pellets were extracted
with methanol. The supernatants were acidified to pH 1.0 with 6 M HCl and extracted three times
with the same volume of ethyl acetate. The extracts were combined and evaporated to dryness
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under reduced pressure. The residues were re-dissolved in methanol. The samples were analyzed
on an Agilent 1200 HPLC instrument (Agilent Eclipse Plus C18, 5 μm, 4.6 mm × 250 mm) using
a linear gradient of 10% to 90% (v/v) acetonitrile-water (containing 0.1% trifluoroacetic acid) over
45 min at a flow rate of 1 mL min-1.

5.2.3 Time-course analysis of the production of 31-36 in E. coli BL21(DE3)/pET28a-stts
For the time-course analysis experiment, E. coli BL21(DE3)/pET28a-stts was cultured in 500
mL of LB medium supplemented with 50 μg mL-1 kanamycin in three 2-L flasks. The cells were
induced and treated with 10 mg mL -1 glucose or sodium pyruvate as described above. The
fermentation broths were sampled (10 mL) at 0, 4, 8, 16, and 24 hr, and the products were analyzed
by HPLC.

5.2.4 Purification and structural characterization of 31-36
To isolate 31-36 for structural characterization, the cultures were scaled up to 1 L and grown
for different time periods. Briefly, 1 mL of seed culture (OD 600=1.0) of E. coli
BL21(DE3)/pET28a-stts was inoculated into 1 L of LB medium containing 50 μg mL-1 kanamycin
and grown to OD600 1.0. 0.2 mM IPTG was then added to induce the expression of StTS. After 24
hr, 10 mg mL-1 glucose or sodium pyruvate was added. After fermentation, the cultures were
extracted as described above.

To isolate these compounds, a typical purification procedure was given below. The crude
extract was fractionated on a silica gel-60 column, eluted with a gradient of methanol-chloroform
(0:100, 1:99, 1.5:98.5, 3:97, 5:95, 10:90, v/v, each 250 mL) to afford 6 fractions. The fractions
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containing the target compounds were further separated by reverse-phase HPLC (Agilent Eclipse
Plus C18, 5 μm, 4.6 mm × 250 mm), eluted with acetonitrile-water at a flow rate of 1 mL min-1.

To isolate compound 31, the culture was maintained under the same conditions for an
additional 8 hr after glucose was fed. The compound was found to be in fraction 4 after silica gel
column chromatography. This fraction was further separated on HPLC with 37% acetonitrilewater. The peak at 16 min was collected to yield 6.4 mg of 31 in pure form. 1H NMR (DMSO-d6):

 12.59 (2H, s, OH-6 and OH-6'), 11.01 (2H, s, OH-8 and OH-8'), 6.99 (2H, d, 2.4, H-9 and H-9'),
6.56 (12H, d, 2.4, H-7 and H-7'). ESI-MS analyses for structure elucidation.

For the purification of compound 32, the incubation time after addition of glucose was 16 hr.
Fraction 5 was found to contain 32 after separation on the silica gel column. The fraction was
subjected to further purification on HPLC, eluted with 34% (v/v) acetonitrile-water. The peak at
13 min was collected, yielding 4.8 mg of 32 in pure form. The purified compound was subjected
to NMR (Tables 9 and 10) and ESI-MS analyses for structure elucidation.

To purify 33 and 34, the incubation time after glucose addition was 24 hr. After silica gel
column chromatography, 33 was present in fraction 4. This fraction was further separated on
HPLC, eluted with 36% (v/v) acetonitrile-water. The peak at 15 min was collected to yield 8.2 mg
of 33 in pure form. 34 was found in fraction 2, which was further separated on HPLC using 35%
(v/v) acetonitrile-water. The peak at 15 min was collected to yield 7.6 mg of 22 in pure form. These
purified compounds were subjected to NMR (Tables 9 and 10) and ESI-MS analyses for structure
elucidation.
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To isolate 35, E. coli BL21(DE3)/pET28a-stts was cultured following the same procedure
except that 10 mg mL-1 sodium pyruvate was added and the broth was extracted at 4 hr after
addition of the nutrient. After silica gel column chromatography, fraction 2 was found to contain
35. The fraction was further separated by HPLC using 33% (v/v) acetonitrile-water. The peak at
13 min was collected to yield 5.7 mg of 35 in pure form. This compound was subjected to NMR
(Tables 9 and 10) and ESI-MS analyses for structure elucidation.

For the purification of 36, the broth was extracted after incubation with 10 mg mL-1 sodium
pyruvate for 24 hr. Fraction 4 was found to contain 36 after silica gel column chromatography.
This fraction was further separated by HPLC using 38% (v/v) acetonitrile-water. The peak at 15
min was collected, yielding 4.5 mg of 36 in pure form. This compound was subjected to NMR
(Tables 9 and 10) and ESI-MS analyses for structure elucidation.

5.2.5 Bioconversion of flaviolin by E. coli BL21(DE3)/pET28a in the presence of glucose or
pyruvate
E. coli BL21(DE3)/pET28a was grown in 400 mL of LB containing 50 g mL-1 kanamycin to
OD600 1.0. The culture was then split equally into four 500-mL flasks, each containing 100 mL of
the culture. Three flasks each were fed with 10 mg of flaviolin, with the remaining one as blank
control. Two of the flaviolin-containing cultures were supplied with 10 mg mL-1 glucose and
sodium pyruvate, respectively. The third one was used as control, to which no nutrient was added.
This experiment was repeated for three times, with three independent replicates in each round.
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5.3 Results

5.3.1 Product analysis of the fermentation broths of E. coli BL21(DE3)/pET28a-stts supplemented
with different nutrients
LB broth is a rich medium that promotes fast growth of bacteria such as E. coli. We have
previously expressed the type III PKS StTS from S. toxytricini in E. coli BL21(DE3) and the
polyketide product was identified as flaviolin (Fig. 25), a spontaneously oxidized product of THN.
The major components in LB medium are tryptone, yeast extract and sodium chloride. Accordingly,
the carbon sources in this medium are not sugars, but catabolizable amino acids [20]. However,
synthesis of a flaviolin molecule requires five units of malonyl-CoA, which is also a substrate for
the primary fatty acid biosynthetic pathway. It remains unclear how extra carbon sources such as
glucose affect polyketide biosynthesis. Since pET28a was used as the expression vector for StTS,
direct addition of glucose into the fermentation broth in the beginning will inhibit protein
expression. Accordingly, glucose was added into the fermentation broth of E. coli
BL21(DE3)/pET28a-stts 24 hr after IPTG induction, thus allowing the desired PKS to be
overexpressed in the E. coli cells. Three different concentrations were tested. As shown in Fig. 26
A, when 1 mg mL-1 (final concentration) glucose was supplemented, a minor peak 31 was
produced after 24 hr, together with the original product flaviolin. When glucose was supplemented
at 5 mg mL-1, three additional products, 32, 33 and 34, were produced. When the concentration
was increased to 10 mg mL-1, same products were observed, excepted that 31 was almost
undetectable. These results indicated that supplement of glucose has led to the production of four
new products in E. coli BL21(DE3)/pET28a-stts.
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Fig. 25 Structures of flaviolin and biosynthesized derivatives (31-36).

It is known that glucose is converted into pyruvate through glycolysis. We next tested whether
supplement of pyruvate in the fermentation broth of E. coli BL21(DE3)/pET28a-stts has the same
effect on product formation. We thus added sodium pyruvate into the IPTG-induced broth of this
strain at three different concentrations. Interestingly, although 31 was observed when 1 mg mL-1
sodium pyruvate was supplied, different products were produced at higher concentrations (Fig. 26
B). At 5 mg mL-1 sodium pyruvate, a new peak 35 was detected, while another product 36 was
synthesized when 10 mg mL-1 sodium pyruvate was supplemented. This result suggested that
different exogenously supplied carbon sources have different effects on polyketide biosynthesis in
E. coli.
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Fig. 26 HPLC analysis (420 nm) of the effects of exogenous glucose (A) and pyruvate (B) on
polyketide biosynthesis in E. coli BL21(DE3). The nutrients were separately supplied to the
fermentation broths of E. coli BL21(DE3)/pET28a-stts at different concentrations (1, 5 and 10 mg
mL-1) 24 hr after IPTG induction. The products were analyzed 24 hr after the addition of the
nutrient. The induced fermentation broth of E. coli BL21(DE3)/pET28a-stts without any
exogenous nutrient was used as the control.

5.3.2 Time course analysis of the production of 31-36 in E. coli BL21(DE3)/pET28a-stts
In order to gain more insights into the production process of these novel flaviolin derivatives,
we conducted a time-course analysis of the product formation in the IPTG-induced fermentation
broths of E. coli BL21(DE3)/pET28a-stts, with or without supplemented nutrients. As shown in
Fig. 27, without any exogenously supplied nutrient (glucose or pyruvate), the major product of E.
coli BL21(DE3)/pET28a-stts was found to be flaviolin at different time points. When 10 mg mL1

glucose was added 24 hr after IPTG induction, new derivatives were generated. While flaviolin

was the only major product at 0 hr (the time when glucose was added), 31 was detected as a new
product at 4 hr. At 8 hr, the amount of 31 decreased while another product 32 was synthesized. At

111

16 hr, product 33 was produced. The amount of 33 increased with time, while that of 32 decreased,
suggesting that 32 might be a precursor of 33. At 24 hr, 34 was produced and 33 became a major
product. 31 was not detectable at 24 hr, likely due to compound degradation. The final pH of the
glucose-supplemented broth was 5.5.

When 10 mg mL-1 sodium pyruvate was added (Fig. 27), 35 was produced as a major product
after 4 hr, with 36 detected as a minor product. The amount of 36 increased with time, while that
of 35 decreased. At 16 hr, 35 became a tiny product and was not detected at 24 hr. In contrast, 36
was the only flaviolin derivative at 24 hr. This suggested that 35 is a precursor of 36 and can be
completely converted to the latter. The final pH of sodium pyruvate-supplemented culture of E.
coli BL21(DE3)/pET28a-stts was determined to be 8.5.

Fig. 27 Time-course analysis of the product formation in E. coli BL21(DE3)/pET28a-stts in the
presence of 10 mg mL-1 glucose or sodium pyruvate. The fermentation broth of E. coli
BL21(DE3)/pET28a-stts without any supplemented nutrient was used as a control. Samples were
collected at 0, 4, 8, 16, and 24 hr and analyzed by HPLC at 420 nm.
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5.3.3 Purification and structural characterization of six flaviolin derivatives
Products 31-36 have UV absorptions similar to flaviolin, suggesting that they are derivatives
of this polyketide compound. To structurally identify these new products, E. coli
BL21(DE3)/pET28a-stts was cultured in large scale supplemented with glucose or sodium
pyruvate. The compounds were purified by open column chromatography and HPLC. ESI-MS
analysis of 31 showed ion peaks [M+H]+ at m/z 411 and [M-H]- at m/z 409, indicating that the
molecular weight of this compound is 410, which corresponds to a dimer of flaviolin. The 1H NMR
spectrum of 31 indicated that it has a symmetrical structure and a comparison of the proton signals
with literature allowed it to be identified as 3,3'-biflaviolin (31, Fig. 28), a known compound
reported in our and others' previous work [4, 21].

Compound 32 was obtained as a red powder. Its molecular weight was determined to be 262
on the basis of the [M+H]+ peak at m/z 263 and [M-H]- peak at m/z 261 in the ESI-MS spectra,
which is 56 mass units larger than flaviolin. The NMR spectra of 32 are similar to those of flaviolin,
except that there are three additional carbon signals, including a ketone group (δ 204.3), a
methylene group (δ 37.0) and a methyl group (δ 29.4). Analysis of the 1H NMR spectrum showed
two aromatic protons (δ 6.53 and 6.97) that belong to H-7 and H-9, respectively, while no signal
for H-3 was found, suggesting that this position has been substituted. An additional CH2 singlet at

 3.55 and a CH3 singlet at  2.17 were found in the high field. These extra proton and carbon
signals suggested that an acetone group has been introduced to the core structure of flaviolin at C3. This was confirmed by the HMBC spectrum. As shown in Fig. 28, the HMBC correlations of
H-1' at δ 3.55 to C-2, C-3, C-4 and C-2', and H-3' at δ 2.17 to C-2' confirmed the connection of the
acetone group with flaviolin at C-3. Thus, 32 was identified as 2,5,7-trihydroxy-3-(2-oxopropyl)-
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naphthalene-1,4-dione. The assigned carbon and proton signals are listed in Tables 11 and 12,
respectively.

Compound 33 was isolated as a red powder. Its molecular weight was determined to be 377
based on the [M+H]+ ion peak at m/z 378 and [M-H]- ion peak at m/z 376 in the ESI-MS spectra.
This is 115 mass units larger than 32, suggesting that it is a derivative of 32 and may contain an
indole group. The 1H NMR spectrum of 33 showed several proton signals in the low field. In
addition to the two known doublet signals (δ 6.49 and 6.90) that belong to H-7 and H-9 of flaviolin,
six proton signals were observed at δ 10.88, 7.54, 7.31, 7.13, 7.03, and 6.95, indicating the presence
of an indole moiety. A CH3 singlet at δ 2.08 and a CH singlet at δ 5.26 were also found in the 1H
NMR spectrum. Consistently, the 13C NMR and DEPT spectra revealed that there were a ketone
group (δ 205.5), a methyl group (δ 28.2), and methylene group (δ 44.8). This suggested that the
acetone moiety is still present, with a CH at C-1' due to the substitution of a proton by an indole
group at this position. Further observation of the HMBC correlations of H-1' to C-3, C-4, C-2', C4', C-5' and C-12', and H-3' to C-2' unambiguously verified the connection of the indole-3-acetone
group to flaviolin at C-3. Thus, this compound was identified as 3-(1-(1H-indol-3-yl)-2oxopropyl)-2,5,7-trihydroxynaphthalene-1,4-dione. The carbon and proton signals were assigned
based on the 2D NMR including HSQC, 1H-1H COSY and HMBC spectra (Fig. 28), and are listed
in Tables 11 and 12.

Compound 34 was obtained as a red powder as well. ESI-MS analysis revealed the [M+H]+
ion peak at m/z 360 and [M-H]- ion peak at m/z 358, indicating that its molecular weight is 359
and the structure might also contain a nitrogen atom. 34 is 18 mass units smaller than 33 and might
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be its dehydrated derivative. Similar to that of 33, the 1H NMR spectrum of 34 also showed the
presence of an indole moiety (δ 11.43, 7.56, 7.46, 7.32, 7.14, and 7.02) and a signal of methyl
group (δ 2.43). However, the proton and carbon signals of CH-1' signal in 33 were not found in
the NMR spectra of 34. Instead, there is a new quaternary carbon signal at δ 114.8, to which H-3'
has the HMBC correlation. Further 2D NMR analysis (Fig. 28) confirmed that a furan ring was
formed between the core structure of flaviolin and indole moiety through a dehydration reaction
of the acetone group with 2-OH. Thus, 34 was identified as 5,7-dihydroxy-3-(1H-indol-3-yl)-2methylnaphtho-[2,3-b]furan-4,9-dione. All the carbon and proton signals were assigned and are
listed in Tables 11 and 12, respectively.

Compound 35 was isolated as a red powder. The molecular weight of this compound was
determined to be 244 on the basis of the [M+H]+ ion peak at m/z 245 and [M-H]- ion peak at m/z
243 in the ESI-MS, which is 38 mass units larger than flaviolin. The 1H NMR spectrum of 35 had
3 proton signals (δ 7.05, 6.48, and 6.13) in the low field that belong to the flaviolin scaffold, with
a new methyl group signal observed at δ 2.40. In the 13C NMR spectrum, three new carbon signals
including two ketone groups and a methyl group were observed at δ 189.5, 168.8 and 10.5,
respectively. Further HMBC analysis (Fig. 28) indicated that a furanone ring was formed, which
includes C-1 and C-2 of the flaviolin scaffold. The position of the methyl group at C-3' was
determined based on its HMBC correlations to C-1, C-1' and C-2'. Therefore, 35 was identified as
6,8-dihydroxy-1-methylnaphtho[2,1-b]furan-2,5-dione. The carbon and proton signals of this
compound were assigned and are shown in Tables 11 and 12, respectively.

115

Compound 36 was obtained as a red powder as well. ESI-MS spectra showed the [M+H]+ ion
peak at m/z 333 and [M-H]- ion peak at m/z 331, indicating that the molecular weight of this
compound is 332, which is 88 mass units larger than 35. The NMR spectra of 36 are similar to
those of 35, also containing the signals of the flaviolin scaffold and furanone ring. However,
additional proton and carbon signals were observed in the NMR spectra of 36. The major
difference between 1H NMR spectra of 35 and 36 are in the high filed. While 35 has the CH3-3'
signal at δ 2.40, the spectrum of 36 showed a CH2 singlet at δ 3.10 and a CH3 singlet at δ 1.41,
suggesting that a different group is attached to C-1'. The 13C NMR spectrum of 36 revealed 16
carbon signals. Thus, this compound has three more carbons than 35. The four carbon signals that
belong to the C-1' side chain were found at δ 35.8 (CH2-3'), 75.2 (C-4'), 176.1 (C-5') and 26.2
(CH3-6'). This side chain and its connection to the furanone ring at C-1' were confirmed by the
HMBC correlations shown in Fig. 28. Therefore, the structure of 36 was characterized as 3-(6,8dihydroxy-2,5-dioxo-2,5-dihydronaphtho[2,1-b]furan-1-yl)-2-hydroxy-2-methylpropanoic acid.
All the carbon and proton signals were assigned based on 1D and 2D NMR spectra, and the data
are listed in Tables 11 and 12.

Fig. 28 Selected 1H-1H COSY and HMBC correlations for 32-36.
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Table 11 13C-NMR (75 MHz) data for 32-36 (DMSO-d6).
13C

position

32
180.2
156.7
117.5
188.8
107.0
163.7
108.1
162.8
108.1
131.9
37.0
204.3
29.4

1
2
3
4
5
6
7
8
9
10
1'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
12'

33
184.1
156.2
120.8
188.8
107.8
163.0
108.3
162.8
108.3
132.3
44.8
205.5
28.2
111.4
124.8

NMR
34
171.5
150.7
129.0
185.2
108.8
164.5
107.5
164.3
108.8
134.5
114.8
157.7
13.0
103.0
126.2

135.7
111.4
120.3
118.5
118.8
127.6

136.0
111.8
121.3
119.2
119.7
126.5

35
138.1
161.9
105.6
189.5
107.2
165.9
106.8
164.4
110.5
128.0
129.6
168.8
10.5

36
139.7
160.9
104.8
188.9
106.2
163.8
105.6
164.6
110.5
129.4
130.2
168.7
35.8
75.2
176.1
26.2

Table 12 1H-NMR (300 MHz) data for 32-36 (DMSO-d6, δ in ppm, J in Hz).
position
3
7
9
1'
3'
5'
6'
8'
9'
10'
11'
6-OH
8-OH
6'-NH

1H

NMR

32

33

34

35

36

6.53 (1H, d, 2.4)
6.97 (1H, d, 2.4)
3.55 (2H, s)
2.17 (3H, s)

6.49 (1H, d, 2.4)
6.90 (1H, d, 2.4)
5.26 (1H, s)
2.08 (3H, s)
7.13 (1H, d, 1.2)

6.50 (1H, d, 2.0)
7.07 (1H, d, 2.0)

6.13 (1H, s)
6.48 (1H, d, 2.0)
7.05 (1H, brs)

6.33 (1H, s)
6.43 (1H, brs)
7.62 (1H, brs)

2.40 (3H, s)

3.10 (2H, s)

7.31 (1H, d, 7.9)
7.03 (1H, t, 7.9)
6.95 (1H, t, 7.9 )
7.54 (1H, d, 7.9)
12.92 (1H, s)
10.88 (1H, s)
10.88 (1H, brs)

7.46 (1H, d, 7.6)
7.14 (1H, t, 7.6)
7.02 (1H, t, 7.6 )
7.32 (1H, d, 7.6)
12.32 (1H, s)
11.21 (1H, s)
11.43 (1H, s)

2.43 (3H, s),
7.56 (1H, d, 2.4)

1.41 (3H, s)

12.50 (1H, s)
10.99 (1H, s)

12.97 (1H, s)
10.73 (1H, s)

13.12 (1H, s)
11.11 (1H, s)
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5.3.4 Bioconversion of flaviolin by E. coli BL21(DE3)/pET28a
We have previously shown that StTS is a type III PKS. It synthesizes THN that can be
spontaneously oxidized into flaviolin. Thus, the synthesis of additional flaviolin derivatives 31-36
is likely due to the endogenous enzymes in E. coli. To confirm this, purified flaviolin was fed into
the IPTG-induced fermentation broth of E. coli BL21(DE3)/pET28a with or without supplemented
glucose or sodium pyruvate (10 mg mL-1). After 24 hr, the cultures were extracted and subjected
to HPLC analysis. As shown in Fig. 29, the E. coli strain harboring the empty pET28a vector alone
did not produce any flaviolin-related compounds (trace i). When flaviolin was added, no
derivatives were observed (trace ii, Fig. 29). When flaviolin and glucose were supplemented, 3234 were produced (trace iii, Fig. 29), suggesting that these novel structures were synthesized by
enzymes of the host and these reactions need to be triggered by glucose. When flaviolin and
sodium pyruvate were added into the induced broth of E. coli BL21(DE3)/pET28a, 36 was
produced (trace iv, Fig. 29). Compared to trace ii, it is obvious that 36 was synthesized by the
bacterial host only when10 mg mL-1 sodium pyruvate was supplied.

Fig. 29 HPLC analysis (420 nm) of the bioconversion of flaviolin by IPTG-induced fermentation
broths of E. coli BL21(DE3)/pET28a. (i) E. coli BL21(DE3)/pET28a as the blank control; (ii) E.
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coli BL21(DE3)/pET28a+flaviolin; (iii) E. coli BL21(DE3)/pET28a+flaviolin+10 mg mL-1
glucose; (iv) E. coli BL21(DE3)/pET28a+flaviolin+10 mg mL-1 sodium pyruvate.

5.3.5 Engineered biosynthetic pathway of flaviolin derivatives
The time-course analysis of the cultures of E. coli BL21(DE3)/pET28a-stts revealed the
sequence of the product formation, based on which we proposed a biosynthetic pathway for these
products (Fig. 30). Briefly, StTS synthesizes THN from five units of malonyl-CoA. THN is then
quickly oxidized by air to yield flaviolin. Two molecules of flaviolin can be coupled through an
oxidation reaction to afford 31. In the presence of exogenous glucose, 32 was first synthesized,
which can subsequently be converted to 33 when excess indole becomes available. An indole
molecule was attached to 32 at C-1' through oxidative coupling to give rise to 33. Indole is a
metabolite from the metabolism of the amino acid tryptophan. It is an important signaling chemical
in E. coli, which regulates the transition of the cells from exponential to stationary phase [22].
When the cells enter stationary phase, they produce indole [23]. This explains why 33 was
produced 16 hr after glucose was added. 34 is formed through a dehydration reaction between the
OH-2 and the OH-2' of the enol form of the indole-3-acetone moiety. Addition of pyruvate into
the fermentation broth of E. coli BL21(DE3)/pET28a-stts led to the synthesis of different products.
The structure of 35 indicated that a molecule of pyruvate was added to flaviolin. When an
additional unit of pyruvate was introduced, 36 was generated. Thus, 35 is proposed to be the
precursor of 6. This was also supported by the time-course analysis results that 35 was the major
product at 4 and 8 hr, but diminished after 16 hr when 36 became the major metabolite.
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It was not expected that addition of glucose and sodium pyruvate gave rise to different
metabolites given the fact that glucose can be converted to pyruvate in the EMP pathway.
Measurement of the final pH of the fermentation broths of E. coli BL21(DE3)/pET28a-stts
provided some clues about the different effects of these two nutrients on the product formation.
The broth with 10 mg mL-1 glucose had a final pH 5.5, while the same amount of sodium pyruvate
made the final pH 8.5. The pH might have affected certain metabolic pathways and the involved
enzymes in E. coli, which led to the production of different flaviolin derivatives. Previous research
has revealed that environmental pH partly influences the cytoplasmic or intracellular pH, which
affects enzyme activity and reaction rates, protein stability, structure of nucleic acids, and many
other biological molecules [24]. Most microbes maintain some degree of pH homeostasis such that
the cytoplasmic pH is maintained within a narrower range, usually close to neutrality. To be
specific, E. coli during optimal growth conditions maintains its cytoplasmic pH within a range of
pH 7.4-7.8 over an environmental pH range of 5.0-9.0 [25, 26]. However, many enzymes have a
very strict optimum pH value and slight change in pH may interfere with their activities and thus
drive the carbon flux to different pathways, leading to the formation of different metabolites.

Our work demonstrated that by supplying different nutrients into the IPTG-induced
fermentation broth of an engineering E. coli strain, novel molecules can be biosynthesized. Key
metabolites from primary metabolic pathways such as pyruvate and indole may be incorporated
into the engineered heterologous biosynthetic pathway to yield “unexpected” novel structures 3236. The enzymes involved in the formation of these products are to be investigated, which will in
turn further facilitate rational design of pyruvate- and indole-containing compounds in E. coli.
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Thus, this work provides a new approach to generating chemical diversity in natural products in
the most commonly used heterologous host E. coli.

Fig. 30 Proposed biosynthetic pathways of 31-36 in E. coli.

5.4 Conclusion
In this work, we engineered a type III PKS into E. coli BL21(DE3) and studied how addition
of glucose or pyruvate influences the product profiles of the engineered strain. Our experiments
showed that addition of glucose did generate four new products 31-34, in addition to the original
product flaviolin resulting from the oxidation of THN. Similarly, two novel flaviolin derivatives
35 and 36 were produced when exogenous sodium pyruvate was supplemented into the induced
fermentation broth of E. coli BL21(DE3)/pET28a-stts. We also found that in a given time period
(24 hr), the concentration of the exogenously supplied nutrients also affects the product profile.
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CHAPTER VI SUMMARY AND ENGINEERING VALUE

6.1 Summary and future plan
This dissertation describes a variety of research approaches to investigate the polyketide
biosynthetic pathway of valuable bioactive molecules. Through heterologous expression, some
key enzymes in the biosynthetic pathways have been identified, and a variety of pharmaceutically
valuable compounds have been produced, such as emodin, endocrocin, chromomycins, flaviolin
and alkylresorcinols. In Chapter II, I constructed a biosynthetic pathway in yeast using a metabolic
engineering approach to produce the bioactive compounds endocrocin and emodin. The pathway
and culture conditions were optimized, leading to the production of emodin and endocrocin
respectively at 592.5 ± 51.6 mg L-1 and 669.3 ± 41.5 mg L-1. For future work, we will try to
introduce more modifying enzymes, such as hydroxylase, methyltransferase and halogenase, into
the biosynthetic pathway of emodin and endocrocin. These enzymes will modify the structures of
endocrocin or emodin, and create more novel bioactive derivatives. In Chapter III, we sequenced
and analyzed the sequence of genomic DNA of S. reseiscleroticus with bioinformatics tools, and
located a putative chromomycin biosynthetic gene cluster which was silent under lab conditions.
Through heterologous expression, we identified the minimal PKS in chromomycin biosynthesis.
The silent biosynthetic pathway was “turned on” by manipulating the regulatory genes. In S.
reseiscleroticus, the chromomycin biosynthetic pathway was activated by disruption of the
repressor gene srcmRII and overexpressing the activator gene srcmRI, yielding an efficient
producing strain of chromomycins A2 and A3. In the future work, we will co-express the tailoring
enzymes with the chromomycin minimal PKS genes in S. lividans K4-114 to confirm their
functions, which will allow us to fully understand the biosynthetic enzymes and facilitate further
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metabolic engineering of this biosynthetic pathway. 5-Alk(en)ylresorcinols have inhibitory effect
on proliferation of cancer cells. In Chapter IV, I heterologously expressed a type III PKS Sl-PKS2
from S. laxum in E. coli, yielding a series of 5-alk(en)ylresorcinols. In the future work, we will
search for other tailoring genes in S. laxum to completely understand the biosynthetic pathway of
the anti-H. pylori compound spirolaxine, and try constructing engineered strains to efficiently
produce spirolaxine. In Chapter V, in addition to engineering the biosynthetic pathways of existing
natural products, I also created a series of new flaviolin derivatives by manipulating the
fermentation conditions of an engineered strain. The natural product flaviolin was synthesized by
a type III PKS StTS that was cloned from S. toxytricini and expressed in E. coli. Addition of
different carbon sources to the induced fermentation broth resulted in the production of several
novel “unnatural” flaviolin derivatives. In the future, additional carbon sources or nitrogen sources
can be tested to create more flaviolin derivatives. Additionally, we can investigate whether the
formation of these novel derivatives is through a chemical reaction or enzyme-catalyzed process.

6.2 Engineering value

6.2.1 Engineered production of endocrocin and emodin in S. cerevisiae
Endocrocin is noted for its industrial applications as dyes, food additives, components of paper
making, and cosmetics as well as for its medicinal uses, including as laxative, anti-inflammatory,
and antitumor agents. In order to improve the production of endocrocin, I engineered its
biosynthetic pathway in S. cerevisiae. A more efficient MβL-TE was added to facilitate the release
of the polyketide product from PKS. For enhanced in situ supply of more malonyl-CoA as
substrate, ACC1 was introduced into the biosynthetic pathway. In Chapter II, after we constructed
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the biosynthetic pathway and further optimized the fermentation conditions, endocrocin was
produced in a titer of 669.3 ± 41.5 mg L-1. Emodin is also an important bioactive compound
possessing significant biological properties such as anti-cancer effects on several human cancer
cells, neuroprotective properties against glutamate (neurotransmitter) toxicity, and antiviral
activity against human cytomegalovirus. The price of emodin (96% purity) is $17 mg -1. Emodin
is derived from decarboxylation of endocrocin. Therefore, we engineered a decarboxylase TpcK
into the pathway to convert endocrine into emodin. Emodin was produced in a titer of 592.5 ± 51.6
mg L-1 by engineering an artificial biosynthetic pathway into S. cerevisiae and optimizing the
fermentation conditions. According to a previous report, emodin was produced 0.6 kg per hectare
in an engineered knotweed after three-years’ cultivation [1]. The production of emodin in my work
is much more time- and cost-effective than knotweed. Compared to emodin production at
approximately 300 mg L-1 in Aspergillus ochraceus [2], the titer in my dissertation research is also
much higher. Our research improved the production of emodin by approximately 97.5%, which
will dramatically reduce the cost of manufacture this compound. Since the P. pastoris expression
system is a more widely approved system in pharmaceutical industry, we also engineered the
biosynthetic pathway of emodin into P. pastoris and optimized the high-density fermentation
conditions. The titer of emodin reached 534.8 ± 42.9 mg L-1. This demonstrated a highly efficient
combinatorial biosynthesis approach to creating various anthraquinones in S. cerevisiae and P.
pastoris.

6.2.2 Engineered production of chromomycins A2 and A3 in S. roseiscleroticus
Chromomycins are natural products with promising antitumor bioactivity, which were
produced by S. roseiscleroticus and other streptomycete species. In this work, I discovered a
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putative biosynthetic gene cluster in S. roseiscleroticus through genomic sequence analysis. This
chromomycin biosynthetic gene cluster was silent, as no chromomycins were produced under lab
conditions. By manipulating two regulatory genes, the biosynthetic pathway of chromomycins A2
and A3 was “turned on”. As shown in Chapter III, chromomycins A2 and A3 were produced by
the engineered strain of S. roseiscleroticus in a titer of 158.3 ± 15.4 mg L-1 and 145.1 ± 15.3 mg
L-1, respectively, after the two regulatory genes were manipulated and the fermentation conditions
were optimized. The price of chromomycin A2 is $220 mg-1 and A3 is $69 mg-1. Chromomycin
A3 was previously produced approximately 110 mg L-1 in engineered S. griseus [3]. The titer in
my research is 31.9% higher than the previously reported, which will significantly reduce the
production cost of chromomycin A3. Therefore, the engineered strain provides an efficient way
for the production of these two pharmaceutically important compounds in the industry.

6.2.3 Engineered production of alkylresorcinols and flaviolin derivatives in E. coli
E. coli is used as a well-established cell factory, which has become the most popular expression
platform worldwide. A type III PKS Sl-PKS2 from S. laxum was heterologously expressed in E.
coli to produce a variety of alkylresorcinols which were found to prevent cells turning cancerous
and inhibit the proliferation of some cancer cells. Another type III PKS StTS was cloned from S.
toxytricini and engineered into E. coli to produce flaviolin that has UV-blocking property. By
manipulating the fermentation conditions, more specifically, adding different exogenous carbon
sources, the engineered E. coli strain produced five novel flaviolin derivatives. These findings
provide an effective approach to creating the chemical diversity in bioactive molecules, which is
important for new drug development.

6.3 References
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APPENDIX B

Fig. B1 The strategy of constructing the plasmid pSUN227.
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APPENDIX C

Table C1. The 1H NMR (300 MHz) data of chromomycins A2 and A3 (CDCl3, δ in ppm, J in
Hz).
Chromomycin A3
δH
Multiplicity
Aglycon
2-H
3-H
4-Hax
4-Heq
5-H
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7-CH3
8-OH
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3-OH
β-D-Chromose C
1-H
2-Hax
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Fig. C1 The UV spectrum and ESI-MS data of SEK15b (MW. 380).

Fig. C2 The UV spectrum and MS data of chromomycin A2 (MW. 1210) and chromomycin A3
(MW. 1182).
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Fig. D1 ESI-MS analysis of in vitro reactions of Sl-PKS2 with various acyl-SNACs (C6-C10) and
malonyl-CoA. I: hexanoyl-SNAC (C6); II: heptanoyl-SNAC (C7); III: octanoyl-SNAC (C8); IV:
nonanoyl-SNAC (C9); V: decanoyl-SNAC (C10).
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Fig. D2 ESI-MS spectra of the structures of alkylresorcinols 16-20.
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APPENDIX E
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Fig. E1 The UV spectra and ESI-MS data of flaviolin and compounds 31-36.

164

APPENDIX F

Fig. F1 The UV spectra and ESI-MS data of encocrocin (1), atrochrysone (7), emodin (2) and nortoralactone (8).
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